使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning. My name is Jonathan and I will be your conference operator today. At this time, I would like to welcome everyone to the Valeant first-quarter 2016 results conference call.
早安。我叫 Jonathan,今天將擔任各位的電話會議主持人。此刻,我謹代表公司歡迎各位參加 Valeant 2016 年第一季財報電話會議。
(Operator Instructions)
(接線員指示)
Ms. Laurie Little, Head of Investor Relations, you may begin your conference.
投資人關係主管 Laurie Little 女士,您可以開始會議。
Laurie Little - Head of IR
Laurie Little - Head of IR
Thanks, Jonathan, and good morning, everyone, and welcome to Valeant's investor conference call where we will be discussing our first-quarter 2016 financial results. Participating on today's call are Joe Papa, Chief Executive Officer; Rob Rosiello, Chief Financial Officer; Dr. Tage Ramakrishna, Chief Medical Officer; Dr. Ari Kellen, Company Group Chairman; Anne Whitaker, Company Group Chairman; and Linda LaGorga, our Treasurer. In addition to the live webcast, a copy of today's slide presentation can be found on our website under the Investor Relations section.
謝謝你,Jonathan,各位早安,歡迎參加 Valeant 的投資人電話會議;我們將在會中討論 2016 年第一季財務結果。今天參與會議的有:執行長 Joe Papa;財務長 Rob Rosiello;醫務長 Tage Ramakrishna 博士;事業群主席 Ari Kellen 博士;事業群主席 Anne Whitaker;以及財務主管(Treasurer)Linda LaGorga。除即時網路直播外,今天的簡報投影片亦可於本公司網站「投資人關係」專區取得。
Before we begin, our presentation today contains forward-looking information. We've asked that you take a moment to read the forward-looking statement legend at the beginning of our presentation, as it contains important information.
在開始之前,提醒各位:我們今天的簡報包含前瞻性資訊。請各位撥冗閱讀簡報開頭的前瞻性陳述說明(legend),其中包含重要資訊。
In addition, this presentation contains non-GAAP financial measures. For more information about the non-GAAP financial measures, please refer to slide 1. Non-GAAP reconciliations can also be found in the press release issued earlier today and posted on our website.
此外,本簡報包含非 GAAP 財務衡量指標。關於非 GAAP 財務衡量指標的更多資訊,請參閱投影片第 1 頁。非 GAAP 調節表亦可於今日稍早發布並張貼於本公司網站的新聞稿中查閱。
Finally, the financial guidance in this presentation is effective only as of today. It is our policy to update our firm guidance only through broadly disseminated public disclosure. With that, I will turn the call over to Joe.
最後,本簡報中的財務指引僅以今日為準。本公司政策為僅透過廣泛公開揭露來更新正式指引。接下來我把電話交給 Joe。
Joe Papa - CEO
Joe Papa - CEO
Thank you, Laurie, and good morning, everyone, and thank you for joining us. Today we'd like to cover the following topics: First, I'd like to share some thoughts following my first month at Valeant then we'll cover the results of the first quarter. Next, I'll walk you through our plans for stabilizing Valeant in 2016, including updating our 2016 guidance. Then we will address the areas of improvement, as well as areas of opportunity. And finally I'd like to tell you why I'm confident in Valeant's future.
謝謝你,Laurie,各位早安,也感謝各位加入我們。今天我們想涵蓋以下主題:首先,我想分享我加入 Valeant 第一個月的一些想法,接著我們將回顧第一季的結果。接下來,我會說明我們在 2016 年穩定 Valeant 的計畫,包括更新 2016 年指引。然後我們將談到需要改善的領域,以及機會所在。最後,我想說明為何我對 Valeant 的未來充滿信心。
In addition to today's prepared remarks we have several slides at the end of the deck in the appendix that we will not cover in today's presentation. Beyond the prepared agenda on slide 3, what I want to do today is really simple. I want to answer four questions: Why did I join Valeant? What is the current situation I found, both the good and the bad? What is our position related to our debt, our liquidity, and the regulatory filings? And why I believe Valeant will be successful in the future.
除了今天的預先準備講稿外,我們在簡報最後的附錄中還有幾張投影片,今天不會在簡報中逐一說明。在投影片第 3 頁既定議程之外,我今天想做的其實很簡單。我想回答四個問題:我為什麼加入 Valeant?我所看到的現況是什麼——好的與不好的?我們在債務、流動性以及監管申報方面的狀況如何?以及我為何相信 Valeant 未來會成功。
Now, let me comment first on that question about debt, liquidity and regulatory filings. We'll have more to say about this later but let me spend a few minutes now. Based on our guidance, we have a solid position with our liquidity. And I expect to be in compliance with the debt covenants throughout 2016 and beyond.
現在,我先就債務、流動性與監管申報這個問題做些說明。我們稍後還會再談,但我先花幾分鐘說明。依據我們的指引,我們的流動性部位相當穩健。我預期在 2016 年以及之後都能符合債務契約條款(covenants)。
Also, we are now planning to file our quarterly information in a timely fashion for the regulatory SEC filings. Time will be our friend at Valeant as we work to improve the Valeant business and, importantly, to pay down debt.
另外,我們目前規劃將按時提交季度資訊,以完成向監管機關(SEC)的申報。隨著我們努力改善 Valeant 的業務,並且更重要的是償還債務,時間將會成為 Valeant 的朋友。
Now, let me start about Valeant and what I found as I was doing my due diligence and joining the Company. I believe that Valeant has a diverse collection of leading healthcare franchises and brands such as Bausch & Lomb, CeraVe and Salix.
接著我談談 Valeant,以及我在進行盡職調查並加入公司時所看到的情況。我相信 Valeant 擁有多元且領先的醫療保健事業與品牌組合,例如 Bausch & Lomb、CeraVe 與 Salix。
As I did my due diligence I discovered Valeant had a very broad geographic global footprint. I believe that our commitment to bring innovative products to the market through an exciting new product pipeline continues to be under-valued and misunderstood and I hope to change that perception.
在進行盡職調查時,我發現 Valeant 擁有非常廣泛的全球地理布局。我相信,我們透過令人振奮的新產品研發管線,致力將創新產品推向市場的承諾,仍被低估且被誤解;我希望能改變這種觀感。
Finally, in my 30-plus years in the pharma business in both branded, generic and OTC parts of the business, I knew many of the Valeant employees before I joined. And now I know even more. In my first 30 days, I've also had the pleasure of meeting many of the talented and dedicated employees that work at Valeant.
最後,在我超過 30 年的製藥產業經驗中,涵蓋品牌藥、學名藥與 OTC(非處方藥)等領域,在加入之前我就認識許多 Valeant 員工。而現在我認識更多人了。在我加入的前 30 天,我也很高興能見到許多在 Valeant 工作、才華洋溢且敬業的同仁。
Globally, we have 22,000 Valeant employees that drive to work every day to focus on improving people's lives. I'm delighted to join the team that focuses on improving people's lives on this mission.
在全球,我們有 22,000 名 Valeant 員工每天上班,專注於改善人們的生活。我很高興加入這個以改善人們生活為使命的團隊。
Like those of you on the phone today, I've also read many of the articles on Valeant. Some have not been favorable. I know it's been a difficult nine months for the team, but I also know we have dedicated leaders who know what is right and necessary to turn this Company around. We'll re-engage our workforce, we'll rebuild our relationships with providers, payers and regain the trust of our debt holders and shareholders.
和今天在線上的各位一樣,我也讀了許多關於 Valeant 的報導。其中有些並不正面。我知道這對團隊而言是艱難的九個月,但我也知道我們有敬業的領導團隊,清楚知道什麼是正確且必要的,能讓公司扭轉局面。我們將重新凝聚員工向心力,重建與醫療服務提供者、支付方(payers)的關係,並重新贏回債權人與股東的信任。
And during the 30 days that I've been with Valeant, I've done just that, met with employees at all levels of the Company, sales leadership, key opinion leaders, many of our key trade partners, prescribers, managed care, GPO. And I've even had a chance to have a couple trips to meet with Congress. In summary for today, my hope is I can capture some of the excitement that I see in Valeant as I walk through today's first quarter but also some of the challenges and the opportunities in front of us.
而在我加入 Valeant 的這 30 天裡,我也確實這麼做了:與公司各層級員工、銷售領導團隊、關鍵意見領袖、許多重要貿易夥伴、開立處方者、管理式醫療(managed care)、GPO(集團採購組織)會面。我甚至也有機會安排了幾次行程與國會會面。總結今天,我希望在帶各位回顧第一季表現時,能傳達我在 Valeant 所看到的一些令人振奮之處,同時也坦誠呈現我們面前的挑戰與機會。
Now, turning to slide 4. We have the Q1 2016 summary, the first-quarter results. Our total revenue was $2.4 billion versus our guidance of $2.3 billion to $2.4 billion. GAAP EPS was a loss of $1.08.
現在請看投影片第 4 頁。我們有 2016 年第一季摘要,也就是第一季的結果。我們的總營收為 24 億美元,對比我們 23 億至 24 億美元的指引區間。GAAP 每股盈餘為虧損 1.08 美元。
Adjusted non-GAAP EPS was $1.27 which falls within the guidance range. GAAP cash flow from operations was $558 million and adjusted EBITDA non-GAAP was just over $1 billion.
調整後非 GAAP 每股盈餘為 1.27 美元,落在指引區間內。GAAP 營運活動現金流為 5.58 億美元,調整後 EBITDA(非 GAAP)略高於 10 億美元。
Now, let me turn the call over to our CFO, Rob, to discuss the quarter in greater detail. Rob?
接下來我把電話交給我們的財務長 Rob,請他更詳細說明本季表現。Rob?
Rob Rosiello - CFO
Rob Rosiello - CFO
Beginning on slide 5 is a financial summary of our GAAP results. As Joe stated, we had a net loss of $1.08 per share for the quarter while GAAP cash flow from operations was $558 million.
從投影片第 5 頁開始,是我們 GAAP 結果的財務摘要。如 Joe 所述,本季每股淨損為 1.08 美元,而 GAAP 營運活動現金流為 5.58 億美元。
COGS was 27% in the quarter with SG&A at 34% and R&D investment was just over $100 million, a record for Valeant. I want to point out that SG&A included $37 million of incremental cost related to Valeant's former CEO of which $25.3 million was for share-based compensation. However, since the performance threshold was not met, no value or shares were ultimately received by the former CEO. SG&A also included $29 million of legal and professional fees in connection with various investigations and related activities.
本季銷貨成本(COGS)占比為 27%,銷售、一般及行政費用(SG&A)占比為 34%,研發(R&D)投入略高於 1 億美元,創 Valeant 歷史新高。我要指出的是,SG&A 包含與 Valeant 前任執行長相關的 3,700 萬美元增量成本,其中 2,530 萬美元為以股份為基礎的薪酬。然而,由於未達績效門檻,前任執行長最終並未取得任何價值或股份。SG&A 亦包含 2,900 萬美元的法律與專業服務費用,與各項調查及相關活動有關。
Turning to slide 6 and following our GAAP presentation, I'd also like to provide a non-GAAP summary. We reported adjusted non-GAAP EPS of $1.27 for the first quarter and you can see the historical adjusted non-GAAP EPS numbers for the past five quarters all under our new tax presentation.
接著看投影片第 6 頁,延續我們的 GAAP 呈現方式,我也想提供一份非 GAAP 摘要。我們第一季的調整後非 GAAP 每股盈餘為 1.27 美元;各位也可以看到在我們新的稅務呈現方式下,過去五個季度的歷史調整後非 GAAP 每股盈餘數據。
Compared to Q1 2015, revenue increased just over $200 million or 9%. The impact of 2015 acquisitions provided $572 million of growth in the quarter. This came from Salix, Marathon, Dendreon and Amoun. This growth was offset by the negative revenue impact of FX of just over $50 million and divestitures of approximately $20 million.
與2015年第一季相比,營收增加略高於2億美元,約9%。2015年收購案的影響在本季帶來5.72億美元的成長。此成長來自Salix、Marathon、Dendreon與Amoun。然而,外匯(FX)帶來略高於5,000萬美元的負面營收影響,以及約2,000萬美元的資產剝離,抵銷了上述成長。
The base business in Q1 declined by $289 million, driven by dermatology including the genericization of Targretin and the transition to Walgreens, the continued decline in our neuro business and declines in our ophthalmology Rx business. COGS increased 3 percentage points, primarily driven by lower derm revenues and the unfavorable impact of gross margins from FX in emerging markets. SG&A increased from 26% to 31%, driven by revenue declines described above as well as an increase in advertising and promotion, for example, DTC advertising, and employee retention of $20 million.
第一季的基礎業務營收下滑2.89億美元,主要由皮膚科業務所驅動(包括Targretin學名藥化以及轉換至Walgreens),以及我們神經科業務的持續下滑與眼科處方藥(Rx)業務的下滑。銷貨成本(COGS)上升3個百分點,主要受皮膚科營收下降,以及新興市場外匯對毛利率的不利影響所致。銷售、一般及行政費用(SG&A)占比由26%升至31%,除上述營收下滑外,亦受廣告與促銷增加(例如直接面向消費者的DTC廣告)以及2,000萬美元員工留任成本增加所影響。
On slide 7, as you know, Valeant currently reports under two segments, developed and emerging markets. Revenues in the developed market were $1.9 billion, an increase of 11% year over year, while operating income declined 8%. While the increase was largely due to acquisitions completed in 2015, we experienced slower uptake in the dermatology recovery than expected. Revenue for US dermatology, and I'm including Obagi and Solta, was $229 million as compared to $399 million in the prior year.
在第7頁投影片,如各位所知,Valeant目前以兩個部門呈報:已開發市場與新興市場。已開發市場營收為19億美元,年增11%,但營業利益下滑8%。雖然成長主要來自2015年完成的收購案,但我們在皮膚科復甦的採用速度低於預期。美國皮膚科營收(我將Obagi與Solta也納入)為2.29億美元,較前一年3.99億美元為低。
Following the launch of the Walgreens program in January, we saw volume flattening and ASPs declining post launch. Overall volume challenges were exacerbated by the loss of refills following the shut down at the end of January of our previous specialty pharmacy relationship, as well as the negative external narrative and some internal disruptions which Joe will cover in more detail later in the presentation.
自1月推出Walgreens計畫後,我們看到出貨量趨於持平,而推出後平均售價(ASP)下滑。整體量的挑戰,因我們在1月底終止先前的專科藥局合作關係而導致續配處方流失而加劇,此外亦受到外部負面敘事以及部分內部干擾影響,Joe稍後會在簡報中更詳細說明。
Revenues for the US GI business were $343 million for the quarter, with gross margins at 85%. Revenues for Xifaxan, the largest Salix product, were $207 million for the quarter which corresponded to a retail TRx increase of 32% over the prior year.
本季美國腸胃(GI)業務營收為3.43億美元,毛利率為85%。Salix最大產品Xifaxan本季營收為2.07億美元,對應零售總處方量(TRx)較前一年增加32%。
Other established brands also showed growth in the quarter and we're pleased the channel inventories for the Salix business have been reduced to 1.5 months and we are now selling to demand. Other areas of note in this segment included continued growth in our US contact lens with Ultra, which was up 58% year over year, aided by a national TV campaign and the launch of Ultra for presbyopia.
其他既有品牌本季亦呈現成長,我們也很高興Salix業務的通路庫存已降至1.5個月,目前我們是依需求出貨。本部門其他值得注意之處包括:我們美國隱形眼鏡業務在Ultra帶動下持續成長,年增58%,受惠於全國性電視行銷活動以及推出適用於老花(presbyopia)的Ultra。
Our US consumer division was awarded the supplier of the year by Walmart, an achievement not easy to attain, while also launching several new products, surveys, ointment and preservation eras MV. Overall vision care was up 9% versus market growth of 1%.
我們的美國消費品事業部獲Walmart頒發年度供應商獎,這項成就並不容易達成,同時也推出多項新產品,包括surveys、ointment以及preservation eras MV。整體視力照護業務成長9%,相較市場成長1%。
Several units achieved strong organic growth, including Provenge, which grew 6% over the prior year and our generics portfolio which grew 14% year over year. There was strong growth in France and the UK, particularly in sales of B&L surgical. We also saw positive momentum from Jublia in Canada which currently enjoys roughly a 60% share.
多個事業單位達成強勁的有機成長,包括Provenge較前一年成長6%,以及我們的學名藥產品組合年增14%。法國與英國成長強勁,尤其是B&L手術產品的銷售。我們也看到Jublia在加拿大的正向動能,目前市占率約60%。
On slide 8, revenues for the emerging market were $442 million for the quarter. This increase in revenue was driven by the 2015 Amoun acquisition, offset by unfavorable foreign exchange of $44 million. The fall in gross margins was driven by FX in countries where the purchasing or manufacturing of goods are in a different currency than where products are sold.
在第8頁投影片,新興市場本季營收為4.42億美元。營收增加主要由2015年收購Amoun所帶動,但被4,400萬美元的不利外匯影響所抵銷。毛利率下滑主要由外匯所致,發生在採購或製造商品所用幣別與產品銷售幣別不同的國家。
Same store organic growth was 2% but would have been nearly 10% if not for the $30 million inventory draw-down in Russia and Poland. Several countries delivered strong organic growth such as Mexico at 8%, China at 19%, and India in double-digits. We did see inventory levels successfully decline in Russia and Poland to approximately 3.5 months from the 4 to 5 months seen throughout 2015.
同店有機成長為2%,但若非俄羅斯與波蘭3,000萬美元的庫存去化,成長本可接近10%。多個國家繳出強勁有機成長,例如墨西哥8%、中國19%,以及印度達雙位數成長。我們也看到俄羅斯與波蘭的庫存水位成功下降,從2015年全年約4到5個月降至約3.5個月。
With that, I will turn the call back over to Joe.
接下來,我把電話會議交回給Joe。
Joe Papa - CEO
Joe Papa - CEO
Thank you, Rob. On slide number 9 what I'd like to do is try to quickly summarize Valeant's current state. We have leading dermatology brands and GI brands and a strong pipeline. We've got great global Bausch & Lomb platform.
謝謝你,Rob。在第9頁投影片,我想做的是快速總結Valeant目前的狀況。我們擁有領先的皮膚科與腸胃(GI)品牌,以及強勁的產品研發管線。我們也擁有優秀的全球Bausch & Lomb平台。
We've got a durable, sustainable business model in both consumer, ophthalmic and branded generics and we have strong cash flow. But we have experienced some significant challenges in our dermatology business as we transition to our access program with Walgreens. We continue to strongly believe in the program and both Walgreens and Valeant are working diligently to correct the issues.
我們在消費品、眼科與品牌學名藥方面擁有穩健、可持續的商業模式,並具備強勁的現金流。但在皮膚科業務方面,隨著我們轉換至與Walgreens的可近性計畫,我們遭遇了一些重大挑戰。我們仍然堅信該計畫,且Walgreens與Valeant正努力不懈地修正相關問題。
Our Salix business is currently running below original expectations but we continue to believe that there remains a sizable opportunity and significant unmet medical need in this area. Unfortunately, negative external attention continues to adversely impact the business and our reputation with patients, physicians and all of you, our shareholders, as well as our distracted organization.
我們的Salix業務目前表現低於原先預期,但我們仍相信此領域仍有可觀機會與顯著未被滿足的醫療需求。不幸的是,外界的負面關注仍持續對業務造成不利影響,並損害我們在病患、醫師以及各位股東心中的聲譽,同時也使我們的組織分心。
On slide 10, to further emphasize how the business is performing, the following chart illustrates that nearly all of our businesses are performing at our expectation, with the exception of the US dermatology and the Salix business.
在第10頁投影片,為了進一步強調業務表現,下圖顯示我們幾乎所有業務的表現都符合預期,唯獨美國皮膚科與Salix業務例外。
On slide 11 we are confident we have a plan to go forward. We have to be realistic as to the impact all this has had on our operations and our financial expectations for the year.
在第11頁投影片,我們有信心已擬定前進的計畫。我們必須務實看待這一切對我們營運以及本年度財務預期所造成的影響。
Our new full-year 2016 guidance as compared to what we previously reported is $9.9 billion to $10.1 billion and adjusted non-GAAP EPS of $6.60 to $7. We expect an adjusted EBITDA number of $4.8 billion to $4.95 billion for 2016. Assumptions surrounding this guidance can be found in the appendix of the presentation posted on the website.
我們新的2016全年財測,相較於先前公布者,營收為99億至101億美元,調整後非GAAP每股盈餘(EPS)為6.60至7.00美元。我們預期2016年調整後EBITDA為48億至49.5億美元。與此指引相關的假設可在網站上所發布簡報的附錄中找到。
Now, I'll turn the call back to Rob.
現在,我把電話會議交回給Rob。
Rob Rosiello - CFO
Rob Rosiello - CFO
Slide number 12 shows where the change is taking place. It is primarily US dermatology and GI with other various small changes attributed to other factors.
第12頁投影片顯示變動發生的位置。主要是美國皮膚科與腸胃(GI),另有其他各種小幅變動歸因於其他因素。
Let me start with dermatology. The current budget represents a $410 million take-down of revenue. This reduction is driven by lower script volume, lower fill rates, speed bumps in the access program, combined with lower ASPs and overall higher managed care rebates.
我先從皮膚科開始。目前的預算代表營收下調4.10億美元。此下調由處方量較低、配藥率較低、可近性計畫中的阻礙(speed bumps),再加上較低的平均售價(ASP)以及整體較高的管理式醫療回扣所驅動。
For Xifaxan, it represents a $390 million reduction, relative to our previous expectations. Xifaxan has delivered strong growth but it is less than our expectations and, we believe, the potential. Disruption, sales force turnover, changes in leadership, shifts in strategy, an increase in enrollments in high deductible plans which we believe for the first time extended into the second quarter, have contributed to our lower forecast. The third bucket of roughly $300 million includes other units, additional pricing reductions, such as the GPO rebates for Nitropress and Isuprel.
就Xifaxan而言,相較於我們先前的預期,代表下調3.90億美元。Xifaxan已交出強勁成長,但仍低於我們的預期以及我們認為其應有的潛力。營運中斷、銷售團隊流動、領導階層變動、策略轉向,以及高自付額保險計畫(high deductible plans)投保人數增加(我們認為這是首次延續到第二季),都導致我們的預測下修。第三個約3.00億美元的項目包含其他事業單位,以及額外的降價因素,例如Nitropress與Isuprel的GPO回扣。
Slide 13 shows what drives the ramp to the mid-point of our guidance. Let me walk through it. So the first is today we're announcing $1.27 in Q1. The second would be assuming a Q1 run rate performance for the rest of the year, pure math, would add $3.81. If we add to that the historic seasonality and typical second-half ramp characteristic in our business, what we might call the typical 40/60, that would add an additional $1.25 and we net out the GPO rebate that we recently announced for Isuprel and Nitropress.
第 13 張投影片顯示了是什麼因素推動我們的表現提升至指引區間的中點。我來帶大家逐一說明。第一點是,我們今天宣布第一季為 1.27 美元。第二點是,假設今年其餘時間都維持第一季的執行率表現,純粹以數學計算,將增加 3.81 美元。若再加上我們業務歷史上的季節性,以及典型的下半年加速特性(我們稱之為典型的 40/60),將再增加 1.25 美元,並扣除我們近期針對 Isuprel 與 Nitropress 所宣布的 GPO 返利。
The fixing derm and Salix and growth acceleration would provide additional $0.50. Again, that would net out the new managed care contracts. Other markets, particularly emerging growth, which we feel very good about, would deliver an additional $0.17. And then we would net out of that subtraction of generic erosion, for example Zegerid, and other potential pricing actions that we might take.
皮膚科業務的修復、Salix 以及成長加速將額外貢獻 0.50 美元。同樣地,這將扣除新的受管醫療合約。其他市場,特別是我們非常看好的新興成長市場,將額外貢獻 0.17 美元。接著我們會再扣除學名藥侵蝕(例如 Zegerid)以及我們可能採取的其他潛在定價措施所帶來的減項。
Take this together, this would deliver the mid-point of our guidance. And we see upsides in improving the ASPs in volumes, particularly in our dermatology business through engagement with independent pharmacies, adjustments to co-pays and buy-downs and improvement in the prior off process.
綜合以上,將可達到我們指引的中點。我們也看到上行空間,來自於改善 ASP 與銷量,特別是在皮膚科業務方面,透過與獨立藥局的合作、調整自付額與降付方案(buy-downs),以及改善事前授權流程。
Now I'd like to turn the call over to Linda, our Treasurer, to discuss our debt and liquidity position.
現在我想把電話會議交給我們的財務主管(Treasurer)Linda,請她說明我們的負債與流動性狀況。
Linda LaGorga - Treasurer
Linda LaGorga - Treasurer
Thanks, Rob. First, focusing on our liquidity. While we have revised our guidance for 2016, our current and forecasted liquidity position remains solid. As of March 31, we had $1.3 billion of cash and as of today we have approximately $1.2 billion of cash.
謝謝你,Rob。首先,聚焦在我們的流動性。雖然我們已修訂 2016 年的指引,但我們目前與預測的流動性狀況仍然穩健。截至 3 月 31 日,我們持有 13 億美元現金;截至今天,我們約有 12 億美元現金。
We remain focused on reducing our permanent debt which includes our term loans and bonds. Year to date, we have repaid $730 million in term loans through various maturity payments, amortization payments and payments using asset sale proceeds. We have $273 million in mandatory payments remaining in 2016 with minimal amortization requirements in 2017.
我們仍專注於降低永久性債務,包括我們的定期貸款與債券。年初至今,我們已透過各項到期償付、攤還付款,以及使用資產出售所得,償還了 7.30 億美元的定期貸款。2016 年尚有 2.73 億美元的強制性付款,2017 年的攤還要求則很低。
Our credit agreement includes two maintenance covenants, a secured leverage ratio and an interest coverage ratio. We are in compliance with both financial maintenance covenants in the first quarter and we continue to expect that we will remain in compliance with both financial maintenance covenants throughout 2016. There are no financial maintenance covenants in our indentures governing our bonds.
我們的信貸協議包含兩項維持性財務契約:擔保槓桿比率與利息保障倍數。第一季我們符合這兩項財務維持性契約,並且我們仍預期在 2016 年全年都將持續符合這兩項財務維持性契約。規範我們債券的契約(indentures)中不包含任何財務維持性契約。
Reducing our total leverage is one of our priorities. Based on our revised 2016 guidance, we expect our net leverage ratio to be approximately 6 times or less by year-end 2016.
降低我們的總槓桿是優先事項之一。根據我們修訂後的 2016 年指引,我們預期截至 2016 年底的淨槓桿比率約為 6 倍或更低。
Moving to slide 15. We remain committed to using the vast majority of our cash flow to pay down debt. Based on our revised guidance, our cash flow available for debt repayment and other purposes has decreased by $500 million from the $2.2 billion in our March investor call and is now $1.7 billion.
接著看第 15 張投影片。我們仍致力於將絕大部分現金流用於償還債務。根據修訂後的指引,我們可用於償債及其他用途的現金流,較 3 月投資人電話會議所提的 22 億美元減少 5 億美元,現在為 17 億美元。
The reduction in our cash available for debt payment and other purposes is less than the reduction in adjusted EBITDA, primarily due to a reduction in the use of cash for working cap. In the first quarter, our working capital was a source of cash. Based on our revised guidance, we are projecting working capital to be approximately neutral to cash flow for the year.
我們可用於償債及其他用途的現金減少幅度,小於調整後 EBITDA 的減少幅度,主要是因為營運資金的現金使用下降。第一季,我們的營運資金是現金來源。根據修訂後的指引,我們預估全年營運資金對現金流的影響大致為中性。
The projected cash flow for debt payment is weighted towards Q2, Q3 and Q4, as we completed the Sprout payment of $500 million in the first quarter. In our March investor call, we said we expected to pay down at least $1.7 billion of permanent debt which is our term loans and bonds. We remain committed to repaying $1.7 billion of permanent debt through our cash flow and proceeds from potential non-core asset sales.
用於償債的預估現金流將偏重於第二、第三與第四季,因為我們已在第一季完成對 Sprout 的 5 億美元付款。在 3 月的投資人電話會議中,我們表示預期至少償還 17 億美元的永久性債務,也就是我們的定期貸款與債券。我們仍致力於透過現金流以及潛在的非核心資產出售所得,償還 17 億美元的永久性債務。
Based on debt repaid to date and our upcoming yet-to-be-paid mandatory Q3 and Q4 amortization payments under our credit agreement, we will have paid over $1 billion of term loans, leaving an incremental $700 million of permanent debt repayment to meet our goal. We continuously monitor the market and will remain opportunistic across our bank debt and senior notes to pursue the best approach to meet our goals. As we look forward into 2017, our cash flow available for debt repayment will improve, as we would expect it to be greater than $2 billion, as we do not expect to have payments similar to the Sprout payment as we focus on our existing operations and reducing our leverage.
根據迄今已償還的債務,以及我們在信貸協議下即將到期但尚未支付的第三季與第四季強制性攤還付款,我們將已償還超過 10 億美元的定期貸款,為達成目標仍需再額外償還 7 億美元的永久性債務。我們持續監控市場,並將在銀行債務與優先票據之間把握機會,採取最佳方式以達成目標。展望 2017 年,我們可用於償債的現金流將改善;我們預期將超過 20 億美元,因為在我們專注於既有營運並降低槓桿之際,預期不會再有類似 Sprout 付款的支出。
With that, I will turn the call back over to Joe.
接下來,我把電話會議交回給 Joe。
Joe Papa - CEO
Joe Papa - CEO
Thank you, Linda. On slide 16 you see Valeant's stabilization plan. I've been at Valeant for approximately one month now and I'd like to outline on this page the areas that we need to address and improve.
謝謝你,Linda。在第 16 張投影片,你會看到 Valeant 的穩定化計畫。我加入 Valeant 大約一個月了,我想在這一頁概述我們需要處理並改善的領域。
I believe it's a three-step process, to be clear. First, the stabilization process of Valeant which I think will take three to six months. That would be followed by a turnaround stage and ultimately a transformation stage that will take a multi-year process for Valeant. Today's discussion's really going to be limited the stabilization plan and what we think are the important elements of that stabilization plan.
我認為這是一個三步驟流程,說清楚一點。第一步是 Valeant 的穩定化過程,我認為需要三到六個月。接著是扭轉(turnaround)階段,最終是轉型(transformation)階段,這將是 Valeant 一個為期多年的過程。今天的討論將主要限於穩定化計畫,以及我們認為該計畫的重要要素。
Number one. We need to drive engagement in the Company. We need to re-recruit Valeant employees back to the Company. We need to add some additional outside talent. And we're going to work very hard to re-engage with our partners, the patients, the prescribers, the payers and investors.
第一。我們需要提升公司內部的投入與參與。我們需要把 Valeant 的員工重新招募回公司。我們需要引進一些額外的外部人才。我們也將非常努力地重新與合作夥伴、病患、開立處方者、付款方以及投資人建立互動與連結。
Number two. We want to reallocate strategic resources at Valeant to fix the dermatology business, accelerate Salix growth which is already quite good, as Rob mentioned, but I just want to clearly reaccelerate that growth.
第二。我們希望在 Valeant 重新配置策略資源,以修復皮膚科業務、加速 Salix 的成長;如 Rob 所提,Salix 的成長已相當不錯,但我想更明確地讓成長再加速。
Number three, we want to refocus R&D dollars into investment for core assets of ophthalmology, dermatology, GI and consumer. We want to manage the neuro and other business for cash generation and to pay down debt.
第三,我們希望將研發(R&D)資金重新聚焦,投資於眼科、皮膚科、腸胃科(GI)與消費性產品等核心資產。我們希望以現金創造為導向來管理神經科與其他業務,並用以償還債務。
Finally, we want to execute on the priorities that we already know to exist. We want to improve patient access and address pricing issues. We want to execute on non-core asset sales to help reduce the complexity of Valeant business. We want to focus on debt reduction and intend to cooperate with all government inquiries and seek expedited resolution.
最後,我們希望執行我們已知存在的各項優先事項。我們希望改善病患可近性並處理定價議題。我們希望推動非核心資產出售,以協助降低 Valeant 業務的複雜度。我們希望專注於降低負債,並打算配合所有政府調查,並尋求加速解決。
On slide 17 we have identified an action plan and begun its implementation for dermatology. First, we must repair our corporate reputation and regain trust with all of our stakeholders. This will be done through a number of initiatives, including CEO actions of customer engagement and overall pricing and access. We also will reiterate our support to the fields of dermatology and podiatry, both R&D and corporate investment.
在第 17 張投影片,我們已針對皮膚科擬定行動計畫並開始執行。首先,我們必須修復公司的聲譽,並重新贏回所有利害關係人的信任。這將透過多項措施達成,包括執行長推動的客戶互動,以及整體定價與可近性。我們也將重申對皮膚科與足病醫學(podiatry)領域的支持,包括研發與公司投資。
We also must rebuild the access with the Walgreen program and the independent pharmacy. We've been launching a new coupon program with independent pharmacies in June and we will continue working with Walgreens to improve the patient and prescriber experiences.
我們也必須重建透過 Walgreens 計畫與獨立藥局的可近性。我們將於 6 月與獨立藥局推出新的折價券計畫,並將持續與 Walgreens 合作,以改善病患與處方醫師的體驗。
We must restore profitability at Walgreens through the implementation of reimbursement and prior authorization support via qualified third parties. We have contracted with a third-party vendor that will take over this process in June.
我們必須透過合格第三方導入給付(reimbursement)與事前授權支援,以恢復 Walgreens 的獲利能力。我們已與一家第三方供應商簽約,該供應商將於 6 月接手此流程。
With respect to dermatology, I want to make sure that you're aware a significant portion of our Walgreens prescriptions have profitability significantly below our internal projections and meaningfully below non-Walgreen prescriptions. In some instances, these prescriptions actually have a negative average selling price. The vast majority of the revenue shortfall in dermatology in our revised guidance relates to this average selling price shortfall.
就皮膚科業務而言,我想確保各位了解:我們在 Walgreens 的處方中,有相當大一部分的獲利能力顯著低於我們的內部預測,且也明顯低於非 Walgreens 的處方。在某些情況下,這些處方的平均售價(ASP)實際上為負值。我們在修訂後指引中,皮膚科的大部分營收缺口都與這項平均售價(ASP)不足有關。
The good news is that we believe this problem is fixable and we are working collaboratively with our partners to address these issues. It is in Walgreens' and Valeant's interest to fix this problem. If we are successful in improving the Walgreens ASP there will be an additional upside to our current derm latest estimate. We will continue to advance our rich pipeline and demonstrate our commitment to the field of dermatology also in terms of the action plans for dermatology.
好消息是,我們相信這個問題是可以解決的,我們也正與合作夥伴協同合作來處理這些議題。解決這個問題符合 Walgreens 與 Valeant 的共同利益。如果我們成功提升 Walgreens 的 ASP,將會為我們目前皮膚科最新預估帶來額外上行空間。我們將持續推進我們豐富的產品研發管線,並且也會在皮膚科的行動計畫方面展現我們對皮膚科領域的承諾。
Now, on slide 18 there are some early indications of recovery. We've begun to see the process to stabilize this business and see some early indications of recovery. We've seen an uptick in prescriptions in May, which obviously is an encouraging sign but we still have a lot more to do. We are just about to launch an access program for independent pharmacies that will improve the patient experience.
現在,在第 18 張投影片上可以看到一些早期復甦跡象。我們已開始看到穩定這項業務的進程,並出現一些早期復甦的訊號。我們在 5 月看到處方量回升,這顯然是令人鼓舞的跡象,但我們仍有很多工作要做。我們即將為獨立藥局推出一項可近性(access)計畫,以改善病患體驗。
On slide 19, as with dermatology, we have a plan to accelerate the Salix franchise. The problem with the Salix franchise, we had significant sales turnover with the Salix integration over the last 12 months. We have appointed a new leader to stabilize the organization and accelerate growth.
在第 19 張投影片上,如同皮膚科一樣,我們也有一項計畫來加速 Salix 事業群。Salix 事業群的問題在於:過去 12 個月在 Salix 整合過程中,我們的銷售團隊出現了顯著的人員流動。我們已任命一位新領導者來穩定組織並加速成長。
We have also launched a new hepatic encephalopathy education and sales material to both doctors and patients. And we have also deployed an additional 67% incremental sales reps for hepatic encephalopathy to drive growth. We have also reached out to 12 major teaching institutions and launched a new educational program about HE. In addition to education, we are improving patient access and adherence through the optimization of our reimbursement hub and other patient assistance programs.
我們也針對醫師與病患推出了新的肝性腦病變(HE)教育與銷售資料。此外,我們也為肝性腦病變配置了額外增加 67% 的銷售代表,以推動成長。我們也已與 12 家主要教學機構接洽,並啟動一項關於 HE 的新教育計畫。除了教育之外,我們也透過優化我們的給付報銷服務中心(reimbursement hub)及其他病患協助計畫,來改善病患可近性與用藥依從性。
On slide 20 you can see that Xifaxan retail TRx was growing 32% versus last year. But we see tremendous opportunity for the brand given the new indication and the continued potential with HE. There remains a significant unmet medical need in HE patients, as experts estimate that up to 5.5 million patients in the US have cirrhosis. Of this population, it's estimated that up to 2.2 million are at the risk of developing overt HE.
在第 20 張投影片上,你可以看到 Xifaxan 的零售 TRx 較去年成長 32%。但鑑於新的適應症以及 HE 的持續潛力,我們認為該品牌仍有巨大的機會。HE 病患仍存在顯著未被滿足的醫療需求,因為專家估計美國多達 550 萬名病患患有肝硬化。在這些人當中,估計多達 220 萬人有發展為顯性(overt)HE 的風險。
Annually, over 600,000 patients are discharged from the hospital with HE being the primary diagnosis. We estimate the total market revenue opportunity in the US for HE is at over $5 billion.
每年有超過 60 萬名病患以 HE 為主要診斷自醫院出院。我們估計,美國 HE 的整體市場營收機會超過 50 億美元。
On the IBSD opportunity, roughly 10% to 15% of the US adult patient population suffers from IBS and 65% of these have a diarrheal component. Despite new treatment options, many of them are undiagnosed and are not treated. This represents another Xifaxan growth opportunity.
就 IBSD 的機會而言,美國成人病患族群約有 10% 至 15% 罹患 IBS,其中 65% 具有腹瀉成分。儘管有新的治療選項,仍有許多人未被診斷且未接受治療。這代表 Xifaxan 的另一個成長機會。
On slide 21 we continue to see steady growth in Xifaxan scripts on a year-over-year basis but to be clear, they are below our previous expectations. The performance of the new sales team should accelerate the franchise in other Salix brands to continue to show additional growth. Finally, we continue to invest in the pipeline opportunities to sustain long-term growth, including oral Relistor.
在第 21 張投影片上,我們持續看到 Xifaxan 處方量以年對年基礎穩定成長,但需要說清楚的是,仍低於我們先前的預期。新銷售團隊的表現應能加速 Salix 旗下其他品牌的事業群,並持續展現額外成長。最後,我們仍持續投資於研發管線機會以維持長期成長,包括口服 Relistor。
Moving to slide 22. Although Valeant has areas that need stabilization and improvement, I believe that we have a solid future ahead. We have a strong global portfolio of brands. We have a plan to fix dermatology and drive momentum in Salix.
接著看第 22 張投影片。儘管 Valeant 仍有需要穩定與改善的領域,我相信我們的未來依然穩健。我們擁有強大的全球品牌組合。我們有一項計畫來修復皮膚科業務並推動 Salix 的動能。
We have a steady performance in consumer, contact lens, dentistry, oncology, generics and in Asia. We have an attractive R&D pipeline that will drive future growth. We have improved our US market access and a strong cash flow generation.
我們在消費品、隱形眼鏡、牙科、腫瘤、學名藥以及亞洲市場皆有穩健表現。我們擁有具吸引力的研發管線,將推動未來成長。我們已改善美國市場可近性,並具備強勁的現金流創造能力。
Let me talk about a few of those. Slide 23 provides a brief view of our numerous Valeant brands and the magnitude of our franchises.
我來談其中幾項。第 23 張投影片簡要呈現我們眾多 Valeant 品牌以及各事業群的規模。
On slide 24 we summarize we have approximately $3.5 billion of consumer-oriented durable products that collectively have operating margins at roughly 37% and growing in the mid single-digits. This would include the Bausch & Lomb products, lens, solutions, as well as CeraVe and other topical products. I will let others speculate on the value of this part of our Valeant business but a durable global growing business with a 37% EBITDA margin is certainly a very valuable asset.
在第 24 張投影片上,我們總結:我們約有 35 億美元的消費導向耐用品(durable products),合計營業利益率約 37%,且以中個位數成長。這包括 Bausch & Lomb 的產品、鏡片、護理液,以及 CeraVe 與其他外用產品。我會讓其他人去推測 Valeant 這部分業務的價值,但一個具全球規模且持續成長、EBITDA 利潤率達 37% 的耐用品業務,無疑是非常有價值的資產。
Slide 25, Dendreon's another valuable but under-appreciated business within our portfolio. Provenge delivers a statistically significant benefit, a 38% improvement in three-year survival rate versus control. Over the past year, the team has turned the business to a profitable, growing business by targeting the right prescribers and improving the gross margin by more than 10%. We expect to see this business continue to grow nicely as urologists now make up 49% of the business and have increased their enrollments for Provenge infusions by 22% year over year in Q1.
第 25 張投影片,Dendreon 是我們投資組合中另一項有價值但被低估的業務。Provenge 帶來具統計顯著性的效益,三年存活率相較對照組提升 38%。在過去一年,團隊透過鎖定合適的開立處方醫師,並將毛利率提升超過 10%,使該業務轉為獲利且成長的業務。我們預期該業務將持續良好成長,因為泌尿科醫師目前占該業務的 49%,且在第一季其 Provenge 輸注的收案(enrollments)年增 22%。
On slide 26, over the past few months there has been much discussion about managed care access across our portfolio. We have made significant progress in forging new relationships with our partners and feel that things are stable for our products. We are improving our commercial access with several key brands, as well as improving our Medicare Part D coverage in the second half of 2016.
在第 26 張投影片上,過去幾個月市場對於我們整體產品組合的管理式醫療(managed care)可近性有許多討論。我們在與合作夥伴建立新關係方面已取得顯著進展,並認為我們產品的狀況已趨於穩定。我們正改善數個關鍵品牌的商業保險可近性,同時也在 2016 年下半年改善我們的 Medicare Part D 覆蓋。
Beginning June 1, Jublia is now covered on AARP without a prior authorization and the Lotemax family of products moved to a preferred brand on the Aetna Medicare Saver Rx plan. Finally, our managed care team is now focusing their efforts to maximize formulary access for our upcoming launch of products.
自 6 月 1 日起,Jublia 現已在 AARP 計畫下獲得給付且不需事前授權(prior authorization),而 Lotemax 系列產品也在 Aetna Medicare Saver Rx 計畫中調整為優先品牌(preferred brand)。最後,我們的管理式醫療團隊目前正聚焦其努力,以在我們即將上市的產品上最大化處方集(formulary)可近性。
In summary, from a US market access perspective, we are well positioned for 2016, 2017 and beyond. Now I'm going to turn the call over to Tage who heads up our R&D operations. Tage?
總結而言,從美國市場可近性的角度來看,我們已為 2016 年、2017 年及更長遠的未來做好良好布局。接下來我將把電話會議交給負責我們研發營運的 Tage。Tage?
Tage Ramakrishna - Chief Medical Officer
Tage Ramakrishna - Chief Medical Officer
Thank you, Joe. On slide 27 you will see a summary of our R&D development programs. I continue to believe that Valeant has one of the most productive R&D organizations in the industry. Unfortunately, our R&D organization is misunderstood because we focus on the results of our pipeline rather than the financial investment.
謝謝你,Joe。在第 27 張投影片上,你會看到我們研發開發計畫的摘要。我仍然相信 Valeant 擁有業界最具生產力的研發組織之一。不幸的是,我們的研發組織常被誤解,因為我們著重的是研發管線的成果,而非財務投入。
This slide is a testament of our output-driven R&D model. We have a significant number of active programs in all of our core therapeutic areas. It is the output and results that matters for patients and physicians which enable us to bring new and improved treatments to patients' lives.
這張投影片證明了我們以產出為導向的研發模式。我們在所有核心治療領域都有大量正在進行的計畫。對病患與醫師而言,重要的是產出與結果,這也使我們能將新的、改良的治療帶入病患的生活。
In 2016, we plan on launching 20 new products. Additionally, on slides 28 and 29, you will see our drug development success rate in dermatology is significantly higher than the rest of the pharmaceutical industry, with 100% success rate in our Phase 3 dermatology development programs as noted on slide 29.
在 2016 年,我們計畫推出 20 項新產品。此外,在第 28 與第 29 張投影片上,你會看到我們在皮膚科的藥物開發成功率顯著高於其他製藥產業;如第 29 張投影片所示,我們的第 3 期皮膚科開發計畫成功率為 100%。
Slide 30. We currently have three products under review at the FDA, two with PDUFA dates next month and one in November. Relistor Oral, which as you know, is the oral formulation of our currently approved Relistor subQ injection for the indications of opioid-induced constipation in patients with advanced illness and patients with chronic non-cancer pain.
投影片30。我們目前有三項產品正在接受 FDA 審查,其中兩項的 PDUFA 日期在下個月,另一項在 11 月。Relistor 口服劑型,如各位所知,是我們目前已核准之 Relistor 皮下注射劑(subQ)的口服配方,適應症為晚期疾病患者以及慢性非癌痛患者的鴉片類藥物誘發性便祕。
Latanoprostene bunod is for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. And finally, Brodalumab is our monoclonal antibody that targets the IL17 receptor antagonist. It is for the treatment of moderate to severe plaque psoriasis for patients who are candidates for systemic therapy or photo therapy.
Latanoprostene bunod 用於降低開角型青光眼或眼部高眼壓患者的升高眼內壓(IOP)。最後,Brodalumab 是我們的單株抗體,標的為 IL17 受體拮抗劑。其用於治療中度至重度斑塊型乾癬,適用於可接受全身性治療或光療的患者。
As you may know, we are currently preparing to go before an FDA Advisory Committee sometime this summer. Brodalumab MAA has also been accepted by the EMEA.
如各位所知,我們目前正準備在今年夏天某個時間點出席 FDA 諮詢委員會(Advisory Committee)。Brodalumab 的 MAA 也已獲 EMEA 受理。
Finally, on our website you will see a quick snapshot of some of our key R&D programs in development. You can also find where we'll be presenting upcoming development data and abstracts at this year's medical conferences.
最後,在我們的網站上,您會看到我們部分關鍵研發(R&D)開發中計畫的快速概覽。您也可以找到我們將在今年醫學會議上發表的即將公布之開發數據與摘要(abstracts)。
I will now turn the call back to Joe.
我現在把電話交回給 Joe。
Joe Papa - CEO
Joe Papa - CEO
Thank you, Tage. In closing, I believe that Valeant is an exceptional Company with a diverse collection of leading healthcare franchises and brands that will make a difference in peoples' lives. We have a steady performance in the majority of our business and we have an attractive R&D pipeline that will drive future growth. We have a stabilization plan and we will execute on this plan.
謝謝你,Tage。最後總結,我相信 Valeant 是一家卓越的公司,擁有多元的領先醫療保健事業群與品牌,將能為人們的生活帶來改變。我們大多數業務表現穩健,且擁有具吸引力的研發(R&D)產品線,將推動未來成長。我們有一項穩定化計畫,並將落實執行該計畫。
We've hit a few speed bumps in certain businesses that we need to you address but we also have an important catalyst for later this year and next year and we are generating strong cash flow. The past year has been tough on everyone but we will work through this period, do the right things and be a stronger Company in the future.
我們在某些業務上遇到了一些小波折,需要加以處理,但我們也有今年稍晚與明年的重要催化劑,同時我們正在產生強勁的現金流。過去一年對每個人都很艱難,但我們會度過這段期間,做正確的事,並在未來成為更強大的公司。
Now, operator, let's open up the call for questions. Operator, please.
現在,接線員,讓我們開放提問。接線員,請。
Operator
Operator
(Operator Instructions)
(接線員指示)
Louise Chen, Guggenheim.
Louise Chen,Guggenheim。
Louise Chen - Analyst
Louise Chen - Analyst
Hi, thanks for the question. My question is on Bausch & Lomb. We get a lot of questions on this business and there hasn't been an update in a while. So just curious how we should think about the EBITDA for this franchise and the growth going forward.
嗨,謝謝讓我提問。我的問題是關於 Bausch & Lomb。我們收到很多關於這項業務的問題,而且有一段時間沒有更新了。所以想請教,我們應該如何看待這個事業群的 EBITDA 以及未來的成長?
Joe Papa - CEO
Joe Papa - CEO
Thank you, Louise. So I think probably the best thing I could say on it is relative to the slide that we had in the presentation. It's a $3.5 billion Company or segment of our Company.
謝謝你,Louise。我想我能說的最好方式,可能是對照我們簡報中的那張投影片。它是一個 35 億美元的公司,或是我們公司的一個事業部門。
Now, to be clear, that also includes some other parts of the business that we think are consumer-oriented, things like the CeraVe, the dermal products, some OTC products, et cetera. But the Bausch & Lomb, the majority of that is ballpark in that $3 billion, $3.5 billion range in terms of a business for us. I do expect that we'll be able to provide some additional guidance as we look at how we do our future guidance but for right now I think best probably I can give you the size of it.
需要說清楚的是,這也包含我們認為偏向消費者導向的其他業務部分,例如 CeraVe、皮膚科產品、一些 OTC 產品等等。但就 Bausch & Lomb 而言,其中大部分對我們來說的業務規模大約落在 30 億到 35 億美元區間。我確實預期,當我們檢視未來的財測指引時,將能提供更多補充指引;但就目前而言,我想我能提供的最好資訊大概就是它的規模。
In terms of the growth rate, I think if you look at the words that we used, a mid single-digit growth rate, the number we used in the presentation was 4% but I think that's the kind of growth we're seeing in it. And as I said, what I think about it most specifically since I joined the Company, it's a very durable business. It's a consumer-oriented business. If you think about the contact lenses, what's in the solutions for all the patients. We've got some vitamins in there in terms of for patients that have ophthalmic vitamins and things like that.
就成長率而言,我想如果你看我們使用的措辭,是「中個位數」成長率;我們在簡報中使用的數字是 4%,我認為這大致就是我們看到的成長。而且如我所說,自從我加入公司以來,我對它最具體的看法是:這是一門非常耐久(durable)的業務。它是消費者導向的業務。如果你想到隱形眼鏡,以及所有患者使用的護理液等產品。我們也有一些維他命產品,例如給患者使用的眼科維他命之類。
We think it's a very stable business. It's growing somewhere in the mid single-digits, 4% is the LTM number for it. And we hope to provide maybe a little bit more guidance on that as we give a little bit more segmentation information as we go forward in the future. Operator, next question.
我們認為這是一門非常穩定的業務。它的成長大約在中個位數,4% 是其過去十二個月(LTM)的數字。我們也希望,隨著未來提供更多分部資訊,能就此提供更多一些指引。接線員,下一題。
Operator
Operator
Tim Chiang, BTIG.
Tim Chiang,BTIG。
Tim Chiang - Analyst
Tim Chiang - Analyst
Hi, Joe. I know you've been at the Company only about a month or so, but I think there's been a lot of questions in terms of whether or not you would pursue a sale of key segments within the Company. Are you guys still focused on just selling non-core assets at this point? How does the guidance reflect the potential for some of your assets being sold at this point?
嗨,Joe。我知道你加入公司大概才一個月左右,但我想市場上有很多問題在於,你們是否會尋求出售公司內的關鍵事業部門。你們目前仍然只專注於出售非核心資產嗎?你們的財測指引如何反映目前部分資產可能被出售的可能性?
Joe Papa - CEO
Joe Papa - CEO
Sure. That is a question that I've heard a couple different times now. I think the way I'd have to say it is that based on 30 days -- and I have to put it as a caveat, it's only been 30 days now -- my review of the business is that really there are some very important core assets within the Company. The core assets that we see are clearly the Bausch & Lomb franchise, the Salix franchise, the derm franchise and the consumer franchise. We view those as core assets where we want to spend behind those, spend behind them both in R&D, capital expenditures in terms of what we're looking at.
當然。這個問題我現在已經聽過幾次了。我必須這樣說:基於 30 天——我得先加註但書,現在確實只有 30 天——我對業務的檢視是,公司內確實有一些非常重要的核心資產。我們認為的核心資產很明確,包括 Bausch & Lomb 事業群、Salix 事業群、皮膚科(derm)事業群以及消費者(consumer)事業群。我們把這些視為核心資產,並希望在其上加大投入,包括研發(R&D)投入,以及我們所評估的資本支出等。
Having said that comment, there are some areas of the Company that I would refer to as non-core. I don't want to go into the specifics of them, but the non-core area are places where we will look to potentially look at asset sales.
在做出上述評論的同時,公司也有一些領域我會稱之為非核心。我不想深入具體細節,但在非核心領域,我們會考慮可能進行資產出售。
We think those asset sales there can help do two things. Number one, it can certainly generate cash to pay down debt. Number two, I think this is also very important one, is that it can reduce some of the complexity of our business by selling off some of these assets that are good assets but they are complex and they do result in a more complex business for us.
我們認為這些資產出售可以幫助達成兩件事。第一,當然可以產生現金用於償還債務。第二,我認為同樣非常重要的是,透過出售其中一些資產——它們是好資產,但相對複雜——可以降低我們業務的複雜度,因為它們確實會讓我們的業務變得更複雜。
I would say right now our view of this is we'll look to sell non-core assets to reduce complexity, to pay down debt. That would both be, I would say, mostly in the area of non-core is what we're going to look at this time. And non-core could be both products and/or some geographies of the world are the areas that we'll look at for, what I would call, non-core asset sales. So I think that's probably about as far as I can go relative to my first 30 days, Tim, with the answer. Operator, next question.
我會說,目前我們的看法是:我們會尋求出售非核心資產,以降低複雜度並償還債務。我會說,這在現階段主要會集中在非核心領域。而所謂非核心,可能同時包含產品,和/或全球某些地理區域;這些都是我們會考慮進行我所稱的「非核心資產出售」的範圍。所以就我加入後的前 30 天而言,Tim,我想我能回答的大概就到這裡。接線員,下一題。
Operator
Operator
Gregg Gilbert, Deutsche Bank.
Gregg Gilbert,德意志銀行(Deutsche Bank)。
Gregg Gilbert - Analyst
Gregg Gilbert - Analyst
Thanks, hi, Joe. I want to try to contain myself to one two-parter. Your largest revenue line, neuro and other, in the quarter was pretty robust. Can you offer any color there and talk about how durable you expect that to be?
謝謝,嗨,Joe。我想盡量把問題控制在一個「兩段式」問題。你們本季最大的營收項目「神經科及其他(neuro and other)」表現相當強勁。你能否提供一些補充說明,並談談你預期這樣的表現能有多持久?
My second part is, Joe, have there been any offers to acquire the Company? And were they above or below the stock price? Perhaps you can describe your philosophy on the independent future of Valeant and how you would handle such approaches if they occurred, particularly in light of media speculation. Thanks.
第二部分是,Joe,有沒有任何收購你們公司的出價?而且出價是在股價之上或之下?也許你可以描述你對 Valeant 獨立發展未來的理念,以及若真的出現這類接觸,你會如何處理,特別是在媒體揣測的背景下。謝謝。
Joe Papa - CEO
Joe Papa - CEO
So let me start with the first part of this question, in terms of revenue and the robustness of the neurology. I think Rob talked a little bit about that in terms -- and I'll probably talk about it. Rob may want to add some more comments.
那我先從這個問題的第一部分開始,談到營收以及神經科業務的穩健性。我想 Rob 已經稍微提到了一些——我可能也會談到。Rob 也許想再補充一些評論。
Certainly, as we put together the plan for neurology and other, it's a very diversified business. It's a business that has a number of different products in it and clearly the performance there has been acceptable. We've got some areas where on product A or product B we're going to do some things.
當然,當我們把神經科及其他業務的計畫整合起來時,這是一個非常多元化的業務。這個業務包含多種不同產品,而其表現顯然是可接受的。我們在某些領域,針對產品 A 或產品 B,會採取一些措施。
For example, as we built our guidance out here, we built into the fact that for two products in there, Isuprel and Nitropress, that we've announced a rebate, a volume discount rebate. And that volume discount rebate will be between 10% to 40% discounts for hospitals that are acquiring Isuprel and Nitropress. We had to build that into the numbers beyond the first-quarter results.
例如,當我們在此建立我們的財測指引時,我們已將其中兩項產品 Isuprel 和 Nitropress 的因素納入考量;我們已宣布提供回饋(rebate),也就是量販折扣回饋。而這項量販折扣回饋,將對採購 Isuprel 與 Nitropress 的醫院提供 10% 到 40% 的折扣。我們必須把這點納入第一季結果之後的數字中。
Secondarily, there is an expectation that Nitropress may go generic sometime in the next 12 months. So we had to build that into our concept for the full year. Rob, anything you want to add to that part?
其次,市場預期 Nitropress 可能在未來 12 個月內某個時間點出現學名藥。因此我們必須把這點納入我們對全年表現的規劃概念中。Rob,你對這部分還有什麼想補充的嗎?
Rob Rosiello - CFO
Rob Rosiello - CFO
I'd just add three points. One is Xenazine which there now has a generic has been going down but actually holding up quite well. And as you point out, Gregg, the business had a very good first quarter.
我只想再補充三點。第一是 Xenazine,目前已經有學名藥,因此一直在下滑,但其實支撐得相當不錯。而且如你所指出的,Gregg,這項業務第一季表現非常好。
TRxs have continued to come down and we obviously announced the GPO rebate of 10% to 40%. So this is a strong business but those are three headwinds that it will have for the rest of the year.
TRx(處方量)持續下滑,而我們也明顯宣布了 GPO 回饋為 10% 到 40%。所以這是一個強勁的業務,但這三項逆風將在今年剩餘時間持續存在。
Joe Papa - CEO
Joe Papa - CEO
Then the final question, Gregg, on acquiring the Company, obviously you know I'm limited to what I can say in answer to that question. I think we've got a very strong future as a Company. As I said, there are some non-core assets that we will look to divest and specifically if they can help us to reduce complexity and also to help us pay down debt. But I think as I've really tried to lay out the story here, I think we've got a very bright future.
至於最後一個問題,Gregg,關於收購本公司,顯然你也知道我能就這個問題回答的內容有限。我認為公司未來非常強勁。如我所說,有一些非核心資產我們會考慮出售,特別是如果它們能幫助我們降低複雜度,也能協助我們償還債務。但我想,正如我在這裡努力鋪陳的故事,我認為我們有非常光明的未來。
Clearly we have some challenges. I mentioned the challenge with the dermatology program and what we're doing with Walgreens and some of the negative ASPs, the average selling prices we're dealing with in dermatology. But I think all those things are fixable. Once we get that behind us, we think the Company has a very bright future and one based on comments Tage made, on our pipeline which I think is misunderstood and I look to move that forward and try to change perception of our pipeline for the future.
很明顯我們確實面臨一些挑戰。我提到皮膚科專案的挑戰、我們與 Walgreens 正在做的事情,以及我們在皮膚科所面對的一些負向 ASP(平均銷售價格)。但我認為這些事情都是可以修正的。一旦我們把這些問題處理好,我們認為公司會有非常光明的未來;而且根據 Tage 的評論,這也建立在我們的產品研發管線之上——我認為外界對此有所誤解——我會推動其向前並嘗試改變市場對我們未來管線的看法。
So I think I'm going to probably limit my comments on any acquisition of the Company other than to say we will look to sell some non-core asset sales, specifically to help us to pay down debt and to clearly to reduce the complexity of our overall business. Operator, next question.
所以,關於任何收購本公司的議題,我大概會限制我的評論;除了說我們會考慮出售一些非核心資產,特別是為了幫助我們償還債務,並且明確降低我們整體業務的複雜度。接線生,下一個問題。
Operator
Operator
Chris Schott, JPMorgan.
Chris Schott,摩根大通。
Wendy Lin - Analyst
Wendy Lin - Analyst
Good morning, this is Wendy Lin on for Chris. Thanks for the question. Can you talk about the few challenges in the dermatology franchise and the Walgreens implementation that need to be addressed? What is driving the profitability challenges? What are the next steps towards stabilizing the franchise? How long do you think it will take before we see meaningful improvement? Thank you.
早安,我是代 Chris 提問的 Wendy Lin。謝謝讓我提問。你能談談皮膚科事業群以及 Walgreens 導入(implementation)方面需要解決的幾個挑戰嗎?是什麼在驅動獲利能力的挑戰?接下來要採取哪些步驟來穩定這個事業群?你認為要多久我們才會看到有意義的改善?謝謝。
Joe Papa - CEO
Joe Papa - CEO
Thank you for the question. I think it is a very important question in terms of what we're trying to do with dermatology. Dermatology, there's two real issues, I think, is the way I'd probably say it. One issue with the program is just ensuring that we continue to get access as we've seen some change in the channel dynamics as we switch from a specialty pharmacy to putting together a program with Walgreens.
謝謝你的提問。我認為就我們想在皮膚科做到的事情而言,這是一個非常重要的問題。皮膚科我認為主要有兩個真正的議題,我大概會這樣說。其中一個議題是,當我們從專科藥局轉換為與 Walgreens 合作建立一個專案時,通路動態出現一些變化;我們需要確保能持續取得可近性(access)。
The Walgreens program is a great concept but it is a new program. With any new program there are speed bumps that you go through as you put together the program. I think both what I've seen so far is that Walgreens and Valeant are very committed to getting these speed bumps ironed out.
Walgreens 的專案概念很棒,但它是一個新專案。任何新專案在建立過程中都會遇到一些小障礙(speed bumps)。就我目前所見,Walgreens 與 Valeant 都非常致力於把這些小障礙排除。
I've already had several calls and in-person meetings with Walgreens in my first 30 days. And I've got a meeting next week with the Walgreens CEO and the US leadership to talk about how we can work through some of these programs, activities that are part of the issues with both the prior authorization, as well as the average selling price.
在我上任的前 30 天裡,我已經和 Walgreens 進行了好幾次電話會議與面對面會議。而我下週也會與 Walgreens 的執行長及美國區領導團隊開會,討論我們如何解決一些專案與活動上的問題,這些問題包含事前授權(prior authorization),以及平均銷售價格。
The average selling price, though, is an issue and I tried to lay that out in my comments. The issue is that there is a percentage of the business where the average selling price is significantly below what we had previously expected as we put the program together. And in fact, in some places that average selling price is negative. By that means, every time a prescription goes out the door we're taping dollar bills to that prescription as it goes out the door.
不過,平均銷售價格確實是一個問題,我也試著在我的評論中把它說清楚。問題在於,有一部分業務的平均銷售價格顯著低於我們在建立該專案時原先的預期。事實上,在某些地方,那個平均銷售價格是負的。這表示每當一張處方離開門店時,我們等於是在那張處方上貼鈔票讓它出門。
That's something that we have to get fixed. I'm confident that it will get fixed. It doesn't make sense for it to continue as is. But until we get that fixed we tried to be realistic in our looking at the dermatology business for the future. Once we get this fixed, and when we get this fixed we are very confident that we'll generate some significant upside to dermatology.
這是我們必須修正的事情。我有信心它會被修正。照目前這樣持續下去是不合理的。但在我們把它修正之前,我們在評估未來皮膚科業務時,試著保持務實。一旦我們把這件事修好,而且當我們修好之後,我們非常有信心皮膚科將帶來顯著的上行空間。
But I be careful about how long it will take because I think that's still something we're trying to work through with our partners. I probably don't want to go into the exact details but I do hope to have meetings in the very near future with our Walgreens counterpart to talk through some of the issues there for that program.
但我會謹慎看待需要多久,因為我認為這仍是我們正與合作夥伴一起推進的事情。我可能不想深入到確切細節,但我確實希望在非常近期內與 Walgreens 對口單位會面,逐一討論該專案的相關問題。
The other program clearly is to make sure we have sufficient couponing out there for independent pharmacies and that's going to happen in June. So that clearly, we think, will be another important part of the program to be fixed.
另一個專案很明確,就是要確保我們對獨立藥局提供足夠的折價券(couponing),而這會在六月發生。因此我們顯然認為,這也會是該專案需要修正的另一個重要部分。
So I think that really tries to address the questions you had relative to the key challenges with our dermatology program and some of the -- speed bumps is the word I use for the Walgreens program. Operator, next question.
所以我想這大致回應了你關於我們皮膚科專案的關鍵挑戰,以及我用來形容 Walgreens 專案的一些——「小障礙」——的問題。接線生,下一個問題。
Operator
Operator
Annabel Samimy, Stifel.
Annabel Samimy,Stifel。
Annabel Samimy - Analyst
Annabel Samimy - Analyst
Hi, thanks for taking my question. And a little bit along those lines, both in dermatology and in GI, we're talking a lot about ASPs being down. But it seems like you had improved that market access for these promoted products in 2016, both for some of the key dermatology products and some of the key Xifaxan products. And the volume trends seem to be stable, if not going up a little bit. So what is it -- maybe more address dermatology but maybe more specifically on Xifaxan, what is it that's causing the net revenues to be much lower than what would be indicated from some of the visible metrics that we see?
嗨,謝謝讓我提問。延續這個方向,在皮膚科和腸胃科(GI)方面,我們談了很多 ASP 下滑。但看起來你們在 2016 年已改善了這些主推產品的市場可近性(market access),不論是一些關鍵皮膚科產品,或一些關鍵的 Xifaxan 產品。而且量的趨勢似乎穩定,甚至略有上升。那麼是什麼原因——也許更針對皮膚科,但更具體地說在 Xifaxan 上——導致淨營收遠低於我們從一些可見指標所推測的水準?
Joe Papa - CEO
Joe Papa - CEO
Well, first and foremost, I want to make sure I address -- the dermatology, let me talk about that first, then I'll get to Xifaxan. On the dermatology, really it is this issue that I talked about, some of the ASPs, or average selling prices, being below what we had expected. But it goes back to the comments that I made on the Walgreens program on the previous call.
嗯,首先也是最重要的,我想確保我先回應——皮膚科的部分,我先談這個,然後我會再談到 Xifaxan。就皮膚科而言,確實是我提到的這個問題,也就是部分 ASP(平均銷售價格)低於我們原先的預期。但這也回到我在上一通電話會議中,針對 Walgreens 計畫所做的評論。
So I'll probably leave that one aside and spend a minute talking about what we're seeing with Xifaxan. I also have Anne Whitaker here who may want to add some additional comments. She's been the individual that's done a great job -- her and her team -- on improving our market access.
所以我可能先把那一題放一邊,花一點時間談談我們在 Xifaxan 上看到的情況。我這邊也有 Anne Whitaker,她可能會想補充一些額外的評論。她——以及她的團隊——在改善我們的市場准入方面做得非常出色。
Suffice it to say, I think that we are very excited about what we see with Xifaxan. But we have to be candid. The perception, or certainly the situation we find ourselves in right now, is the product is under-performing where we expected it to go. But to be clear, it's up 32%. So I think 32% is a great number year over year in total prescriptions.
簡而言之,我認為我們對於 Xifaxan 的表現非常振奮。但我們也必須坦白。目前的觀感,或者說我們現在所處的情況,是這個產品的表現低於我們原先預期的走勢。但要說清楚,它仍然成長了 32%。所以我認為,以總處方量年增 32% 來看,是一個很好的數字。
But as we looked out for the full year, we have seen some disruption. The disruption was in the sales force. Over the last 12 months we had sales force disruption. As we looked at that sales force disruption we addressed it. We put a new leader in. We put incremental sales force effort behind Xifaxan. We think that's going to be an important part of the solution.
但當我們展望全年時,我們確實看到了一些干擾因素。這些干擾來自銷售團隊。在過去 12 個月,我們的銷售團隊出現了變動與不穩定。在檢視這些銷售團隊的干擾後,我們已經加以處理。我們任命了新的領導者。我們也在 Xifaxan 上投入了額外的銷售團隊資源。我們認為這將是解決方案中很重要的一部分。
But there is some ASP questions that were really as a result of some of what I would refer to as gaining some additional access and gaining preferred access which we think are good tradeoffs. But Anne, you may want to make a comment a little bit more about that.
不過也有一些 ASP 的疑問,主要是因為我們所謂爭取到更多准入、以及取得優先准入所帶來的結果;我們認為這些是良好的取捨。但 Anne,你或許可以就這部分再多做一些評論。
Anne Whitaker - Company Group Chairman
Anne Whitaker - Company Group Chairman
I think we've improved the access. Of course, Xifaxan had good access but we had some cleaning up to do to ensure that all the plans had the full labels, including the IBSD indications as well. And so we do see a number of prior authorizations for Xifaxan.
我認為我們已經改善了准入。當然,Xifaxan 原本就有不錯的准入,但我們需要做一些整理,確保所有保險計畫都涵蓋完整適應症標籤,包括 IBSD 的適應症。因此我們確實看到 Xifaxan 有相當數量的事前授權(PA)。
What we experienced, I think, as we came into the first part of the year was just a transition actually with the vendor who was supporting us with our PA process. And then, secondly, we know that high deductible health plans that more patients enrolled in them this year than previous years. And when a product like Xifaxan you see the impact there as well.
我認為我們在年初時所經歷的,首先其實是支援我們 PA 流程的供應商發生了轉換。其次,我們也知道今年加入高自付額健康保險計畫的病患比往年更多。像 Xifaxan 這樣的產品,也會因此受到影響。
So I feel good about the access going forward. I feel good about our hub services going forward as well. I believe we cleaned up some of the label issues, or labeling that the plan did not have updated.
所以我對未來的准入狀況感到樂觀。我對我們未來的 hub 服務也同樣有信心。我相信我們已經把一些標籤問題整理好了,也就是保險計畫端尚未更新的標籤/適應症資訊。
Annabel Samimy - Analyst
Annabel Samimy - Analyst
Thank you.
謝謝。
Joe Papa - CEO
Joe Papa - CEO
Thank you. Operator, next question.
謝謝。接線員,下一個問題。
Operator
Operator
Andrew Finkelstein, Susquehanna Financial.
Susquehanna Financial 的 Andrew Finkelstein。
Andrew Finkelstein - Analyst
Andrew Finkelstein - Analyst
Good morning, thanks for taking the question. I was hoping you could address a bit more about some of the trends outside the US. There's certainly a lot of focus on key products you have here. You talked about the importance of the larger global footprint. I think you gave some details on the amount of destocking in the first quarter, preferably on an organic basis.
早安,謝謝讓我提問。我希望你們能再多談一些美國以外市場的趨勢。大家當然很關注你們在這裡的關鍵產品。你們也談到更大規模的全球布局的重要性。我想你們提供了一些第一季去庫存的細節,最好是以有機基礎來看。
The Amoun acquisition was a sizable contributor offset by the destocking. If you could talk about what that business looks like going forward and how to evaluate what the run rate is forward and how you think you can leverage it as you move forward (technical difficulty).
Amoun 的收購是相當大的貢獻來源,但被去庫存所抵銷。如果可以的話,請談談該業務未來的樣貌、如何評估未來的運行水準(run rate),以及你們認為在往前推進時可以如何加以槓桿運用(技術問題)。
Joe Papa - CEO
Joe Papa - CEO
Thank you, thanks for the question. You were breaking up a little bit. I think the real question was to focus on what's happening outside the US, what's happening with emerging markets and where are we with that relative to both the growth rate. But also just how we are looking at it when you take out the headwinds and the tailwinds out of the emerging markets numbers and some of the products there.
謝謝,謝謝你的問題。你的聲音有點斷斷續續。我想真正的問題是聚焦在美國以外發生了什麼、在新興市場發生了什麼,以及相對於成長率我們目前處於什麼位置。同時也包括,當你把新興市場數字中的逆風與順風因素,以及其中一些產品的影響剔除後,我們是如何看待的。
So number one, the Bausch & Lomb franchise in the emerging markets continues to perform very strongly. One of the things that we had to do is add some incremental capacity for some of our new contact lenses because the performance has been very strong with the products. We are very pleased with that.
第一,新興市場的 Bausch & Lomb 事業群持續表現非常強勁。我們必須做的一件事,是為我們一些新的隱形眼鏡增加額外產能,因為這些產品的表現非常強。我們對此非常滿意。
Number two, I would say -- that was especially in Asia -- number two, I think one of the comments Rob made I think is really appropriate here to say. Although GAAP revenues were up 4%, if you take out some of the normalization of the inventory question, same-store sales would have been growing at about 10%. So we think that's a really strong performance in emerging markets.
第二,我會說——這在亞洲尤其明顯——第二點,我認為 Rob 先前提到的一個評論在這裡非常貼切。雖然 GAAP 營收成長 4%,但如果把庫存問題的正常化影響剔除,同店銷售本來大約會成長 10%。所以我們認為這是新興市場非常強勁的表現。
Number three, what I'd probably say that I think is an important comment before asking Rob if he wants to add anything, is that the other important point I would say about our ex-US or emerging markets segment, is that much of it is either Bausch & Lomb brands which is obviously, we think, has a very durable business or they are branded generics. The combination of both of those, we think, are very durable assets. And I think that's one of the real important points about the Valeant ex-US business.
第三,在我請 Rob 看他是否要補充之前,我想先說一個我認為很重要的觀點:我們的美國以外或新興市場事業中,很大一部分要不是 Bausch & Lomb 品牌——我們認為這顯然是非常具持久性的業務——要不就是品牌學名藥。這兩者的組合,我們認為都是非常具耐久性的資產。我認為這也是 Valeant 美國以外業務非常重要的一點。
It's either in Bausch & Lomb which has many consumer-type assets which we think are very durable. Or it's in the branded generic business which also has a very durable business.
它不是在 Bausch & Lomb——其中有許多我們認為非常具耐久性的消費型資產——就是在品牌學名藥業務,而那同樣也是非常具耐久性的業務。
So I think for both those reasons, as we think about the future, we're very excited about what the opportunity is there because the durability or sustainability of both these business segments of Bausch & Lomb and also branded generics. Rob, anything you want to add to the emerging market segment question?
因此,基於這兩個原因,當我們思考未來時,我們對那裡的機會感到非常興奮,因為 Bausch & Lomb 以及品牌學名藥這兩個業務板塊都具備耐久性或可持續性。Rob,關於新興市場板塊的問題,你有什麼想補充的嗎?
Rob Rosiello - CFO
Rob Rosiello - CFO
I appreciate the question. From a regional point of view Latin America has seen continued good growth, as has North Asia. And then if you go inside the regions, you have bright spots, as I mentioned, in parts of Europe. I do think this is an area, and as we mentioned, when you make that correction of the inventory draw-down in Russia and Poland, you see overall emerging growth to the levels that I think we've had before, of nearly 10%.
謝謝你的提問。從區域角度來看,拉丁美洲持續有不錯的成長,北亞也是如此。如果再深入到各區域內部,如我提到的,在歐洲部分地區也有亮點。我確實認為這是一個領域,而且如我們所提到的,當你把俄羅斯與波蘭的庫存去化(inventory draw-down)做調整後,你會看到整體新興市場成長回到我認為我們過去曾有的水準,接近 10%。
Andrew Finkelstein - Analyst
Andrew Finkelstein - Analyst
Thanks. If I could slip in a clarification on two things on guidance. There was a change in the expected working capital build for this year. If you could clarify that. And does guidance include any revenue or costs for the key PDUFA products, the Vesneo or Relistor that could be approved and launched this year? Thanks.
謝謝。如果可以的話,我想就財測(guidance)插入兩點釐清。今年預期的營運資金增加(working capital build)有所變動。能否請你們說明一下?另外,財測是否包含任何關鍵 PDUFA 產品(Vesneo 或 Relistor)在今年可能獲批並上市所帶來的營收或成本?謝謝。
Joe Papa - CEO
Joe Papa - CEO
Why don't I turn the first part of that question to Linda on the working capital and then I'll take the second part.
不如我把第一部分關於營運資金的問題交給 Linda,然後我再回答第二部分。
Linda LaGorga - Treasurer
Linda LaGorga - Treasurer
Sure. On working capital as we talked about before, we would expect -- we usually look at where revenues are going. And with the change to revenues relative to last year, while one could even potentially project there, we could have potentially projected a source of cash. At this point, looking at the year and how things have progressed, we're projecting it's going to be neutral to cash. Just think of it relative to where revenues were in 2015 versus now and the growth between those two years.
好的。關於營運資金,如同我們之前談過的,我們會預期——我們通常會看營收的走勢。而由於相較去年營收有所變動,理論上甚至可能推估出我們可能會有現金來源。但就目前來看,綜合今年的情況與進展,我們預估對現金的影響將是中性。你可以把它理解為:相對於 2015 年的營收水準與現在的營收水準,以及這兩年之間的成長幅度。
Joe Papa - CEO
Joe Papa - CEO
And Linda, the comment was about some of the milestones like for Verota and some of the other things. Those are also built in at this time.
而且 Linda,那個評論是關於一些里程碑,例如 Verota 以及其他一些事項。這些目前也都已經納入。
Linda LaGorga - Treasurer
Linda LaGorga - Treasurer
Correct. So if you look on --
沒錯。所以如果你看——
Andrew Finkelstein - Analyst
Andrew Finkelstein - Analyst
Sorry to interrupt. I was asking if there was any revenue or launch cost in the guidance.
抱歉打斷一下。我是在問指引裡是否包含任何營收或上市成本。
Joe Papa - CEO
Joe Papa - CEO
Okay. It was more than the milestones. There is launch cost in there, but to be clear, the Verota product is a late in the year 2016 -- late 2016 PDUFA date. So I don't want to suggest -- there's no revenue at this time and we're going to get ready for launch, but there's not an actual launch. That will be planned sometime in early 2017, to be clear.
好的。不只是里程碑而已。裡面有包含上市準備成本,但要說清楚,Verota 產品是在 2016 年年底——2016 年較晚的 PDUFA 日期。所以我不想暗示——目前沒有營收,我們會為上市做準備,但並沒有實際上市。為了說清楚,那將會規劃在 2017 年初的某個時間。
Andrew Finkelstein - Analyst
Andrew Finkelstein - Analyst
Thanks very much.
非常感謝。
Joe Papa - CEO
Joe Papa - CEO
No revenue. Okay, next question.
沒有營收。好的,下一個問題。
Operator
Operator
Umer Raffat, Evercore ISI.
Umer Raffat,Evercore ISI。
Umer Raffat - Analyst
Umer Raffat - Analyst
Thank you for taking my questions. First one for Rob, if I may. Rob, can you confirm the covenants on interest coverage are $4.7 billion, that you implied EBITDA currently? And more importantly, where do you think it is in 2017 starting second quarter? Does it approach $5 billion or not? That's the first and probably the most important question I'm getting as well.
謝謝讓我提問。如果可以的話,第一個問題問 Rob。Rob,你能否確認利息保障倍數的契約條款(covenants)是以 47 億美元為門檻,也就是你所暗示的目前 EBITDA?更重要的是,你認為 2017 年從第二季開始會是多少?會接近 50 億美元嗎,還是不會?這是第一個、也可能是我這邊最重要的問題。
One for Joe. Joe, I just want to understand what exactly is the EBITDA for Bausch and for Salix? I know there's that slide 24 in there that implies a certain EBITDA margin. But I just want to understand, in dollars what is Bausch and what is Salix right now?
一個問題給 Joe。Joe,我想了解 Bausch 與 Salix 的 EBITDA 到底各是多少?我知道你們有第 24 頁投影片暗示某個 EBITDA 利潤率。但我想了解的是,以金額來看,Bausch 現在是多少、Salix 現在是多少?
And finally for Anne. Anne, where exactly are you guys right now with managed care conversations on the commercial side specifically? Thank you.
最後一個問題給 Anne。Anne,你們目前在商業端、特別是與管理式醫療(managed care)的洽談進度到底到哪裡了?謝謝。
Joe Papa - CEO
Joe Papa - CEO
We'll try to answer your one-part question, Umer. (laughter) But try to get to it. First of all, the question on the covenants and, Linda, you want to take that part of the question, please.
Umer,我們會試著回答你這個「一題多問」的問題。(笑聲)但我們會盡量回答到。首先是關於契約條款的問題;Linda,請你先回答這部分好嗎。
Linda LaGorga - Treasurer
Linda LaGorga - Treasurer
Sure. Umer, there is not one number for the covenants as you would expect. It's an LTM calculation. It's going to vary by quarter. Most importantly, as we said, based on our current guidance, we expect to remain in compliance of our financial maintenance covenants for the remainder of the year.
當然。Umer,契約條款不像你想的那樣只有一個數字。它是以 LTM(過去十二個月)來計算。因此會隨季度而變動。最重要的是,如同我們所說,依據我們目前的指引,我們預期在今年剩餘期間會持續符合我們的財務維持型契約條款。
Umer Raffat - Analyst
Umer Raffat - Analyst
What about 2017?
那 2017 年呢?
Linda LaGorga - Treasurer
Linda LaGorga - Treasurer
We have not provided 2017 guidance at this point.
我們目前尚未提供 2017 年的指引。
Umer Raffat - Analyst
Umer Raffat - Analyst
Okay. But could it approach $5 billion, the covenant, starting second-quarter 2017 when the interest coverage threshold approaches 3X?
好的。但它會不會接近 50 億美元——也就是契約門檻——從 2017 年第二季開始,當利息保障倍數門檻接近 3 倍時?
Linda LaGorga - Treasurer
Linda LaGorga - Treasurer
Umer, we have not given 2017 guidance and what you're asking is not clear to me.
Umer,我們沒有給 2017 年指引,而且你問的內容我不太清楚。
Joe Papa - CEO
Joe Papa - CEO
Let me try to summarize a little bit. Linda, if I say anything incorrectly make sure you correct me. It obviously has a lot of variability based on the LTM. Ballpark it's in that -- for the 2016 -- ballpark it's in the range of somewhere approximately $4.7 billion. But there can be some variability and we've got some comfort with where we are versus that number in a very simplistic way. There's a lot more details that go into that but conceptually it's somewhere in that relative range.
我試著稍微總結一下。Linda,如果我說得不對請務必糾正我。它顯然會因為 LTM 而有很大的變動。粗略來看,在 2016 年——粗略大概是在約 47 億美元左右的區間。但會有一些變動;用非常簡化的方式來說,我們對目前相對於那個數字的位置有一定把握。當然其中還有更多細節,但概念上大致是在那個相對範圍內。
I'm going to bridge to the next question about EBITDA on Bausch & Lomb and Salix. We're not at this time prepared to put forward the exact EBITDA numbers for each individual business. The reason I gave the Bausch breakout -- and it was really more consumer because it was both Bausch and some of our derm businesses -- is that I wanted to give a perspective on what I think is a very durable business in terms of what we have with Bausch & Lomb in terms of it being predominantly consumer. There's some obviously parts of it that are not consumer.
我接著回答下一個關於 Bausch & Lomb 與 Salix 的 EBITDA 的問題。我們目前還沒有準備好提出各個單一事業的精確 EBITDA 數字。我之所以把 Bausch 拆出來——而且其實更偏向消費端,因為那包含 Bausch 以及我們部分皮膚科事業——是因為我想提供一個觀點:我認為我們的 Bausch & Lomb 以消費端為主,是一個非常具韌性的事業。當然其中也有一些部分不是消費端。
But I do think that durability is an important part of really a very valuable asset and that's why we gave the operating margins for the Bausch & Lomb business. I think by any stretch of any valuation model, that would be a very valuable asset for the Company and that's really the reason I gave it. We're not going to give out the specifics, though, on the Salix at this time.
但我確實認為這種韌性是非常有價值資產的重要組成,因此我們才提供了 Bausch & Lomb 事業的營業利潤率。我認為不論用任何估值模型來看,這對公司而言都是非常有價值的資產,這就是我提出它的原因。不過,我們目前不會提供 Salix 的具體數字。
Look to, though, the future that we will look to provide more detailed information as we look at the appropriate way to guide for the future. But based on the 30 days, I think we'll leave it at that. And then, Anne, there's a question on the managed markets you want to comment on?
不過展望未來,當我們以適當方式為未來提供指引時,我們會考慮提供更詳細的資訊。但以這 30 天的情況來看,我想我們就先到這裡。接著,Anne,關於管理式市場(managed markets)的問題,你要不要補充?
Anne Whitaker - Company Group Chairman
Anne Whitaker - Company Group Chairman
Yes, Umer, your question was where are we in the discussions with the managed markets, the payers and such. And so we've had a lot of discussions over the past 9 to 10 months and I'm very proud of what the team has accomplished. I can safely say that I feel our portfolio is secure for 2016, based on the discussions that we've had with regards to commercial and then with any -- of course no changes with Part D for this year.
好的,Umer,你的問題是我們在與管理式市場、付款方等的討論目前進展到哪裡。過去 9 到 10 個月我們進行了大量討論,我對團隊的成果感到非常自豪。我可以很有把握地說,基於我們就商業端所進行的討論,我認為我們 2016 年的產品組合是穩固的;當然,今年的 Part D 也沒有任何變動。
Now, I say that with a caveat that payers often will do category reviews on a quarterly basis. So we could get a notice from a payer that they decided to do a category review for Q4 or something this year. But that's the situation that every Company is in.
不過我也要補充一點:付款方常常會按季度進行品類審查(category review)。所以我們可能會收到某個付款方通知,表示他們決定在今年第四季之類的時間做品類審查。但這是每家公司都會面臨的情況。
So our conversations today with the team and with our payer customers are focused on 2017. We have our bids in for Part D. And for commercial for 2017 it varies by plan. Some we're just doing extensions. Some we're doing category reviews as they come up. But I feel very good about the access we have today and that we'll be building on that for 2017.
因此,我們今天與團隊以及付款方客戶的對話重點是在 2017 年。我們已經提交了 Part D 的投標;而 2017 年的商業端則依各個計畫而異。有些我們只是做延展。有些則是在出現時就進行品類審查。但我對我們目前的可近性(access)很有信心,而且我們會在 2017 年持續在此基礎上再加強。
Joe Papa - CEO
Joe Papa - CEO
Thank you, Anne.
謝謝你,Anne。
Umer Raffat - Analyst
Umer Raffat - Analyst
Thank you very much.
非常感謝。
Joe Papa - CEO
Joe Papa - CEO
Operator, next question.
接線員,下一個問題。
Operator
Operator
David Risinger, Morgan Stanley.
David Risinger,Morgan Stanley。
David Risinger - Analyst
David Risinger - Analyst
Thanks very much. I have a question with respect to the negative ASPs. I guess it's multi-part and I apologize, but could you just explain why there are negative ASPs, how you will fix that, and then whether there will be any negative impact on Rx trends as a result of raising ASPs? Thank you.
非常感謝。我有一個關於 ASP 為負的問題。我想這是多段式問題,先說聲抱歉;但你能否解釋為什麼會出現負的 ASP、你們會如何修正,以及提高 ASP 是否會對處方量(Rx)趨勢造成任何負面影響?謝謝。
Joe Papa - CEO
Joe Papa - CEO
Sure. David, this is a multi-part question that I'll try to give my best towards. What we've done is first and foremost, I'll say we are very excited about the Walgreens program and we think we've got a great partner in Walgreens and we're looking to work through some of these questions.
當然。David,這是個多段式問題,我會盡力回答。我們做的事情是——首先我要說,我們對 Walgreens 的方案感到非常振奮,我們認為 Walgreens 是很棒的合作夥伴,我們也希望一起把這些問題釐清並解決。
The program, as you know, is a very innovative program, it's a 20-year program. And naturally when you put something together that's innovative, you're going to experience some speed bumps. And that's the way I would describe what we see today, is just some speed bumps between as we put together different parts of the program.
如你所知,這個方案是一個非常創新的方案,是一個 20 年期的方案。而當你推出創新的做法時,自然會遇到一些小波折。我會用「小波折」來形容我們今天看到的情況,也就是在我們把方案的不同部分整合起來時,過程中出現了一些小波折。
The program -- and I'll try to do it as briefly as I could -- when you come forward there are different patients that walk in the door. Some are clearly covered by commercial insurance. Some of them are covered but there is a prior authorization in place. Some of them are just simply cash paying customers. Depending on which type of customer you are, you're going to enter into a certain pathway for how your prescriptions are reimbursed and what they look like.
這個計畫——我會盡量簡短說明——當你走進來時,進門的病患類型各不相同。有些很明顯是由商業保險承保。有些雖然有承保,但需要事前授權。有些則只是單純自費的顧客。取決於你屬於哪一種類型的顧客,你會進入一條特定的流程路徑,決定你的處方如何獲得給付(報銷)以及呈現方式。
The issue that we find is that as we went through this, there are some customers, patients, that as they go through this pathway we find that we're receiving a reimbursement or not receiving reimbursement depending on what's happening with that patient, what's happening with the prior authorization, whether the prior authorization gets rejected or not gets rejected. That is causing some of what we would refer to as a negative ASP. That is then driving down the ASP with the Walgreens program versus our non-Walgreens customers.
我們發現的問題是,在我們梳理這個流程時,有些顧客、病患在走這條路徑時,我們會依據該病患的情況、事前授權的進展、事前授權是否被拒絕等因素,出現收到或收不到給付(報銷)的情形。這造成了我們所稱的負向 ASP。進而使得 Walgreens 計畫的 ASP 相較於我們非 Walgreens 的顧客被拉低。
It is our you attempt, and the reason I believe it can be fixed is that we now have the data to look at that. We know exactly where it's coming from. We know the types of patient issues that we can address. And we can work towards that in terms of trying to improve the overall program and, importantly, the ASPs. That's the reason why I'm very comfortable I can fix this, we can work very closely with Walgreens to fix it.
我們的努力方向——也是我相信可以修正的原因——是我們現在已有資料可以檢視這件事。我們清楚知道問題來源。我們知道可以處理的病患類型問題。我們也能朝這個方向努力,改善整體計畫,並且重要的是改善 ASP。這就是為什麼我非常有信心可以把它修好;我們可以與 Walgreens 非常密切合作來修正。
I can't exactly give you what's going to happen with the Rx trends because that would be a speculation that I'm not yet prepared to do. But I will say that we understand what can be done with the ASPs and we know the types of patients that this is impacting and we'll put together a program in place and work with our partner to get that resolved. I do think -- the bottom line is we do think it's fixable.
我無法精確告訴你處方量(Rx)趨勢會如何發展,因為那會是我目前尚未準備做出的推測。但我可以說,我們了解 ASP 可以怎麼改善,也知道這影響到哪些類型的病患;我們會建立一套方案並與合作夥伴一起把問題解決。我認為——歸根結底——我們確實認為這是可以修正的。
David Risinger - Analyst
David Risinger - Analyst
Great. And then in terms of the second-half generics program, is that going to happen or not?
了解。那麼關於下半年學名藥計畫,會推動還是不會?
Joe Papa - CEO
Joe Papa - CEO
The generics, there is a generic program which we referred to, I think it was called Plan B. It is scheduled for later this year and we are working closely with the Walgreens team to make that happen.
學名藥方面,我們先前提到有一個學名藥計畫,我想它叫做 Plan B。它排定在今年稍晚推出,我們正與 Walgreens 團隊密切合作以促成落地。
Once again, it's a very novel concept. It's a concept that is based on having more dispensing of our branded products in place of a generic. We do think there's a large part of value, especially with the prescriber base. Because I think the prescribers -- I clearly believe there are some important vehicle differences with -- especially in dermatology products. So we do look forward to working through that program with Walgreens. But once again, it's slated nor the second half of the year at this time.
再說一次,這是一個非常新穎的概念。其概念是以更多我們的品牌產品取代學名藥的調劑。我們認為其中有很大一部分價值,特別是在處方醫師端。因為我確實相信——尤其在皮膚科產品上——在載體等方面存在一些重要差異。因此我們很期待與 Walgreens 一起推進這個計畫。但同樣地,目前它仍排定在今年下半年。
David Risinger - Analyst
David Risinger - Analyst
Thank you.
謝謝。
Joe Papa - CEO
Joe Papa - CEO
Operator, next question.
接線員,下一個問題。
Operator
Operator
David Amsellem, Piper Jaffray.
David Amsellem,Piper Jaffray。
David Amsellem - Analyst
David Amsellem - Analyst
Thanks. A question on the US neuro and other segment. A lot of these products are off-patent or going off patent. Can you talk about the extent to which we'll see generic competition, either this year or next year on some of the key products?
謝謝。我想問美國神經科及其他事業部(US neuro and other segment)。這裡很多產品已經過專利期或即將過專利期。你能談談我們在今年或明年會在一些關鍵產品上看到學名藥競爭的程度嗎?
Put another way, for products like Nitropress or Isuprel. Should we think about generics coming this year or next year? And you how you're thinking about the erosion of that business due to competition. Thanks.
換個說法,像 Nitropress 或 Isuprel 這類產品。我們應該預期今年或明年會出現學名藥嗎?以及你們如何看待競爭對該業務造成的侵蝕。謝謝。
Joe Papa - CEO
Joe Papa - CEO
I'll start and, Rob, if there's things you want to add to this. This is something we have looked at very closely. We've looked at the total US neuro business. Really it's a diversified product business, is probably the best way, because it's not just a neurology business. As you point out, there are a number of products that are off-patent or soon to be off-patent.
我先回答,Rob,如果你有要補充的也請加入。這是我們非常仔細評估過的議題。我們檢視了整體美國神經科業務。更貼切的說法是它是一個多元化的產品業務,因為不只是神經科。如你所指出,有不少產品已過專利期或即將過專利期。
We do expect the generic competitors specifically on Nitropress and Isuprel. We expect them really sometime in the next 6 to 12 months and that is the current expectation. There are some additional generics that we expect in our portfolio. They tend to be in some of the other areas, some dermatology products like Ziana and other products that we do expect some generics and we built that into our guidance for 2016 and beyond. Rob, anything you want to add to what I said?
我們確實預期 Nitropress 和 Isuprel 會出現學名藥競爭者。依目前預期,大約會在未來 6 到 12 個月內出現。我們也預期在產品組合中還會有一些其他學名藥進入。它們多半在其他領域,例如一些皮膚科產品像 Ziana 等;我們確實預期會有學名藥,並已將其納入我們對 2016 年及之後的財測指引。Rob,你有要補充我剛才說的嗎?
Rob Rosiello - CFO
Rob Rosiello - CFO
Just the three. Zegerid, our current expectation is Q3. Isuprel, Nitropress and Virazole, our expectation is early in 2017.
就這三個。Zegerid,我們目前預期在第三季。Isuprel、Nitropress 和 Virazole,我們預期在 2017 年初。
David Amsellem - Analyst
David Amsellem - Analyst
Thank you.
謝謝。
Joe Papa - CEO
Joe Papa - CEO
Operator, next question.
接線員,下一個問題。
Operator
Operator
Cindy Guan, Goldman Sachs.
Cindy Guan,高盛。
Cindy Guan - Analyst
Cindy Guan - Analyst
Hi, thanks very much. I was wondering if you could give more color on the performance in ophthalmology Rx this year and what's the outlook there? Then secondly, have you had any conversations recently with the rating agencies in terms of what they're looking for in determining whether they would downgrade or remove the negative outlook? Thank you.
嗨,謝謝。我想請你多談一些今年眼科處方(ophthalmology Rx)的表現,以及那邊的展望如何?第二,你們最近是否與信評機構有任何對話,了解他們在判斷是否要調降評等或移除負向展望時,會看哪些條件?謝謝。
Joe Papa - CEO
Joe Papa - CEO
I'll start with the performance of the ophthalmic Rx. I also have Ari here with me. Ari, if you want to add any comments you're welcome to do that as well. I'll turn the rating agency question to Linda.
我先談眼科處方的表現。我這邊也有 Ari 一起。Ari,如果你想補充也歡迎。信評機構的問題我會交給 Linda。
On the question of the ophthalmic Rx, I think probably the most important thing to say there is that we've got some new products coming into the portfolio. Specifically, the product that Tage mentioned, latanoprostene bunod, is we think, a really exciting product. The data on the use of products for glaucoma is actually that latanoprost or Xalatan, a product that actually came from my past when I was with Pharmacia, is still the market leader. It still has ballpark two-thirds of the market is in the treatment of glaucoma is in the area of latanoprost, otherwise known as Xalatan.
關於眼科處方的問題,我想最重要的一點是,我們的產品組合將有一些新產品加入。具體來說,Tage 提到的 latanoprostene bunod,我們認為是一個非常令人振奮的產品。就青光眼用藥的資料而言,latanoprost 或 Xalatan——這個產品其實與我過去在 Pharmacia 的經歷有關——仍然是市場領導者。在青光眼治療市場中,latanoprost(也就是 Xalatan)大約仍占到約三分之二的市場。
We have a product that is better than -- or we believe that will be better than Xalatan or latanoprost. And that is the reason that we're very optimistic in terms of the future.
我們有一個產品優於——或我們相信將會優於——Xalatan 或 latanoprost。這也是我們對未來非常樂觀的原因。
Now, to be clear, we need to get it approved and we are awaiting the FDA process for the approval on that. But I do think, though, that latanoprostene bunod that Tage talked about, is really exciting part of our future.
當然要說清楚的是,我們需要先取得核准,目前正在等待 FDA 的審查核准流程。但我確實認為,Tage 談到的 latanoprostene bunod,會是我們未來非常令人振奮的一部分。
Ari, is there anything else you want to talk about? I know we've got a number of programs we're putting together for market access with our ophthalmic business. Anything else you want to add?
Ari,你還有什麼想補充的嗎?我知道我們正在為眼科業務的市場准入制定一些方案。你還有什麼要補充的嗎?
Ari Kellen - Company Group Chairman
Ari Kellen - Company Group Chairman
yes, maybe a couple points, Joe. One is the three flagship brands or segments, the Lotemax franchise, Prolensa and Besivance. All performed well from a share point of view in Q1. Lotemax and Prolensa grew the monthly scripts 6% and 2%, respectively, both gaining share in the overall market. Besivance declined on a TRx basis 5% but actually gained share in the branded segment.
是的,Joe,或許補充兩點。第一,我們三個旗艦品牌或事業區塊:Lotemax 系列(franchise)、Prolensa 和 Besivance。在第一季從市占角度看都表現良好。Lotemax 和 Prolensa 的月度處方量分別成長 6% 與 2%,兩者在整體市場中都提升了市占。Besivance 以 TRx(總處方量)計算下滑 5%,但實際上在品牌藥區隔中市占有所提升。
Joe Papa - CEO
Joe Papa - CEO
Okay, thank you. And Linda, there was a question on the rating agencies and recent conversations.
好的,謝謝。Linda,關於評級機構以及近期溝通方面有個問題。
Linda LaGorga - Treasurer
Linda LaGorga - Treasurer
Sure, Cindy, we continue to have regular dialogue with both S&P and Moody's who cover us. And as you would expect, they will, from those dialogues and their individual work, make their individual assessments.
當然,Cindy,我們持續與涵蓋我們的 S&P 與 Moody's 保持定期對話。而且如你所預期,他們會根據這些對話以及各自的工作,做出各自的評估。
Joe Papa - CEO
Joe Papa - CEO
Thank you, Linda. Operator --
謝謝你,Linda。接線員——
Cindy Guan - Analyst
Cindy Guan - Analyst
Were the two included in guidance or no? Relistor and latanoprost? Were those included in guidance assuming they get approved in July?
那兩個有納入財測指引嗎,還是沒有?Relistor 和 latanoprost?是否在假設 7 月獲批的情況下納入指引?
Joe Papa - CEO
Joe Papa - CEO
We did include them but at a very small rate. Obviously reflecting putting some type of probability weighting on -- we expect to get them approved. Exact timing you always want to make sure you're somewhat conservative in timing. But yes, they're included but very small at this time.
我們有納入,但比重非常小。顯然是反映了某種機率加權——我們預期會獲批。至於確切時點,你總是希望在時間上稍微保守一些。但有的,已納入,只是目前占比很小。
Cindy Guan - Analyst
Cindy Guan - Analyst
Okay, thank you.
好的,謝謝。
Joe Papa - CEO
Joe Papa - CEO
Next question, operator.
下一個問題,接線員。
Operator
Operator
David Maris, Wells Fargo.
Wells Fargo 的 David Maris。
David Maris - Analyst
David Maris - Analyst
Hi, Joe, my questions have to do with transparency which is what you started the call with. A few things. First, in mid-May you reaffirmed first-quarter guidance but didn't reaffirm the year. Can you walk us through why you didn't withdraw guidance at that point?
嗨,Joe,我的問題與透明度有關,也就是你在電話會議一開始提到的。幾點。第一,5 月中旬你重申了第一季指引,但沒有重申全年。你能否說明一下,為什麼當時沒有撤回指引?
Secondly, why no GAAP EPS guidance? It seems like providing GAAP and then building to non-GAAP is more in keeping with the SEC's goal and use of GAAP and non-GAAP.
第二,為什麼沒有提供 GAAP EPS 指引?看起來先提供 GAAP,再銜接到 non-GAAP,會更符合 SEC 對 GAAP 與 non-GAAP 使用的目標。
And then third, what did the SEC subpoena ask for? And what are they investigating?
第三,SEC 的傳票要求提供什麼資料?他們在調查什麼?
Joe Papa - CEO
Joe Papa - CEO
Okay. I'll start with the commentary on guidance and then the commentary, Rob, if you want to make some comments specifically to the GAAP question that David asked. Let me start with guidance.
好的。我先就指引的評論開始,然後 Rob,如果你想針對 David 提到的 GAAP 問題補充一些看法。我先從指引談起。
So transparency, I do believe it's a very important part and something I clearly continue to hope to improve the transparency of our numbers. Today we report in two areas and I hope to look at that in terms of both the developed markets and the emerging markets and look to provide some additional clarity. As what we did with today, a little bit of a start just on what we said about the Bausch & Lomb and consumer franchise and also Dendreon. My hope is to provide greater transparency over time.
關於透明度,我確實認為這非常重要,也是我明確希望持續提升我們數字透明度的部分。目前我們以兩個領域進行揭露,我希望從已開發市場與新興市場兩方面來檢視,並提供更多清晰度。就像我們今天所做的,算是一個小小的開始,例如我們談到 Bausch & Lomb 與消費者事業,以及 Dendreon。我希望隨著時間推進能提供更高的透明度。
On the specific question of -- I joined the Company on May 2. My first 30 days have been filled with, David, is to really get a much better understanding of the business. I've been doing business reviews with all of the businesses and I really wanted to make sure I understood what was up, what was down.
就你提到的具體問題——我是在 5 月 2 日加入公司。David,我前 30 天主要是在更深入理解這個業務。我已對所有業務進行業務檢視,並且真的想確保我了解哪些在上升、哪些在下降。
As with any business, and certainly the Valeant business is no different, there's some things that are going up and there's some things that are coming down. And before I made any changes in numbers I felt it was most important to really understand the businesses from A to Z, to really understand where are we with the business and why are we there and importantly what are the action plans. That's why to me, as I talked about it, I really talked about the concept of what I was doing with this business, really being a stabilization of the Company in the near term, then moving from stabilization to turnaround and then finally going to transformation.
如同任何企業,當然 Valeant 的業務也不例外,有些事情在變好,也有些事情在變差。在我對數字做任何調整之前,我認為最重要的是從 A 到 Z 充分理解各項業務:我們目前處於什麼狀態、為什麼會在這個狀態,以及更重要的是行動計畫是什麼。因此對我而言,正如我所談到的,我談的是我對這家公司所做工作的概念:短期先讓公司穩定,接著從穩定走向扭轉,最後走向轉型。
My comments today are limited only to the stabilization portion of the program and activities because I think that is clearly the first area that needed the attention. I think that's a three- to six-month process. And then we'll bridge to the turnaround and the transformation.
我今天的評論僅限於計畫與活動中的「穩定」階段,因為我認為那顯然是第一個需要關注的領域。我認為那是一個三到六個月的過程。然後我們會銜接到扭轉與轉型。
But my comments about the guidance were it takes a lot of work to really understand what's happening in the business, especially one that has the complexity that the Valeant business has. And I've been working very diligently in my first 30 days to make sure I did that. Rob, also some questions on the SEC, the GAAP numbers and --
但我對指引的評論是:要真正理解業務正在發生什麼,需要做大量工作,尤其是像 Valeant 這樣複雜的業務。我在加入後的前 30 天一直非常努力,確保我完成這件事。Rob,另外還有一些關於 SEC、GAAP 數字以及——
Rob Rosiello - CFO
Rob Rosiello - CFO
Let me start with the GAAP. We find for our investors it is more informative to guide to the non-GAAP. And we don't feel we can accurately predict the GAAP guidance. In terms of the SEC investigation --
我先從 GAAP 談起。我們認為對投資人而言,提供 non-GAAP 指引更具資訊性。而且我們認為無法準確預測 GAAP 指引。至於 SEC 調查——
David Maris - Analyst
David Maris - Analyst
If I could just interrupt for a second. What you're saying is it's easier to guide to non-GAAP adjusted earnings than GAAP earnings, or that's what investors want, which is that?
我可以打斷一下嗎。你的意思是,相較於 GAAP 盈利,提供 non-GAAP 調整後盈利的指引比較容易,還是說那是投資人想要的,也就是哪一個?
Joe Papa - CEO
Joe Papa - CEO
I'd say it the following way. I'd say our history has been, as with many companies, David, is that we've guided to the adjusted numbers and I think that's really the way we did it in the past and we'll continue to do it for the future.
我會這樣說。我們過去的做法是——和許多公司一樣,David——我們提供的是調整後數字的指引;我認為過去一直是這樣做,未來也會繼續如此。
The final part of your question, David, was the SEC letter that -- what's the issue there. The letter that we received concerned the Company's former relationship with Philidor, its accounting practices and policies and any public disclosures on the matters with the question that we had from the SEC. That was what we are addressing and will continue to work with the SEC.
你問題的最後一部分,David,是關於 SEC 來函——那裡的議題是什麼。我們收到的信函涉及公司過去與 Philidor 的關係、其會計實務與政策,以及就相關事項所做的任何公開揭露,這些都是 SEC 向我們提出的問題。這就是我們正在處理的內容,並將持續與 SEC 合作。
As I said, as a matter of policy, we will work with all government inquiries and try to be cooperative and, importantly, get those resolved as quickly as possible to put those behind us and move forward. That's been my goal, as I stated in my previous comments, and I just probably reiterate at this point. Operator, next question.
如我所說,作為政策,我們會配合所有政府機關的詢問,並努力合作;更重要的是,盡可能快速解決,將這些事情拋諸腦後並向前邁進。這一直是我的目標,正如我先前評論所述,我在此大概再重申一次。接線員,下一個問題。
David Maris - Analyst
David Maris - Analyst
Thank you.
謝謝。
Operator
Operator
Irina Koffler, Mizuho.
Mizuho 的 Irina Koffler。
Irina Koffler - Analyst
Irina Koffler - Analyst
Hi, thanks for taking the questions. Can you talk about how you think about the cash reserves needed to address all the ongoing litigation? And if all of these potential legal expenses would impact your future debt repayment? That's question one.
嗨,謝謝讓我提問。你能談談你們如何評估為應對所有進行中的訴訟所需的現金準備嗎?以及這些潛在法律費用是否會影響你們未來的債務償還?這是第一個問題。
Then wondering if you could comment on Addyi and how it's doing? And if there's any contractual reason why you can't stop promoting that or why you want to be in this business? Thanks.
另外想請你評論一下 Addyi 的情況以及目前表現如何?以及是否有任何合約上的原因使你們不能停止推廣,或為什麼你們想要繼續做這門業務?謝謝。
Joe Papa - CEO
Joe Papa - CEO
Let me start on the cash reserves. Linda, you can add anything. I think there's two parts to this question. Number one is some of the issues that we're dealing with to address the litigation. And I said number one, we can't predict the exact outcome of any litigation. Obviously these are more longer-term in duration. But you I do expect, as I said in the call earlier, we're going to absolutely cooperate with all government inquiries and, importantly, we're going to try to resolve them as quickly as possible and put them behind us.
我先從現金準備談起。Linda,你也可以補充。我認為這個問題有兩個部分。第一是我們正在處理的一些事項,用以應對訴訟。我也說過第一點,我們無法預測任何訴訟的確切結果。顯然這些是較長期的。但我確實預期,正如我在稍早的電話會議中所說,我們會完全配合所有政府機關的詢問;更重要的是,我們會努力盡快解決並把它們拋在腦後。
On the question, though, in terms of cash reserves, I think the important point I will add to the question, because I think it's getting to your question's really important, is that the real important issue is we get beyond 2016 and get into 2017. We'll have less, what I would call, contingent payments and milestone payments from a business development point of view. So we'll have actually more cash to put towards debt repayment as we think about the future.
不過就現金準備的問題而言,我想補充一個重點,因為我認為這切中你問題的核心:真正重要的是我們要走過 2016 年並進入 2017 年。屆時,從業務開發的角度來看,我們會有較少我所謂的或有付款與里程碑付款。因此,展望未來,我們實際上會有更多現金可用於償還債務。
And I think that's probably an important comment as people think about where we are with our liquidity, where we are with our debt covenants a as we get to 2017. We won't have some of the milestone payments and/or contingent liabilities that we've had in the past. We'd be able to pay down more debt for the future.
我認為,當大家思考我們目前的流動性狀況、以及在邁向2017年時我們的債務契約限制(covenants)時,這可能是一個重要的評論。我們將不會再有過去曾有的一些里程碑付款和/或或有負債。我們將能在未來償還更多債務。
On the final question, part of your question was Addyi. We think Addyi's still a very good product and we're excited about what the opportunity is. It candidly needs some additional activities and Anne and the team are working hard and trying to make those happen. And Ari and the team, everybody's working to really take a look at what's required there and what's going make that product a successful product for the future.
關於最後一個問題,你的問題其中一部分是關於Addyi。我們認為Addyi仍然是一個非常好的產品,我們也對其機會感到興奮。坦白說,它需要一些額外的推動作為,Anne和團隊正努力推進並嘗試促成這些事情。而Ari和團隊、所有人都在努力真正檢視那裡需要什麼,以及什麼將使該產品在未來成為成功的產品。
And I think that's probably about as far as I'll say right now. We still think it's a very good pruned we'll look forward to continuing to put more resources behind it in the future to make it a successful product. Operator, next question.
我想我目前大概就說到這裡。我們仍然認為這是一個非常好的產品,我們期待未來持續投入更多資源來支持它,使其成為成功的產品。接線員,下一個問題。
Operator
Operator
Douglas Tsao, Barclays.
Douglas Tsao,巴克萊。
Morgan Williams - Analyst
Morgan Williams - Analyst
Hi, this is Morgan Williams on for Doug. I was hoping to dig in a little deeper to the managed care contracting. I was wondering if you could provide some clarity on whether you're still focused on bundled contracts or whether you're now looking to contract on a product-by-product basis? And then on that point, how you can we start to think about expansion and rebates as you try to improve access in derm and GI?
嗨,我是Morgan Williams,代替Doug發問。我希望更深入了解一下管理式醫療(managed care)的合約簽訂。我想請問你們是否仍然聚焦於打包式合約(bundled contracts),或是現在改為以單一產品逐項簽約?另外就此而言,當你們試圖改善皮膚科與腸胃科(derm and GI)的可近性時,我們應該如何開始思考擴張與回扣(rebates)?
And then one quick follow-up on a previous question. Does the negative ASP that you're seeing through the Walgreens program affect the Walgreens activity fees or what they would receive from Valeant? Thanks.
另外,針對先前一個問題再追問一點。你們透過Walgreens計畫看到的負向ASP,是否會影響Walgreens的活動費(activity fees),或他們從Valeant那裡會收到的款項?謝謝。
Joe Papa - CEO
Joe Papa - CEO
Sure. I'm going to ask Anne to first address the managed care contracts. The only thing I'll say up front on that is clearly that Anne and her team have done a great job of getting the access that we need for managed care today. So we're in good shape with where we need to be today relative to -- as you're thinking about trying to model our business, we think we've got what we need today going into the future. But Anne, anything you want to add?
好的。我先請Anne回答管理式醫療合約的部分。我先在前面補充一句:很明顯,Anne和她的團隊在取得我們目前所需的管理式醫療可近性方面做得非常好。因此,就我們目前需要達到的狀態而言,我們的狀況良好——當你在嘗試建立我們業務模型時,我們認為就邁向未來而言,我們今天已具備所需條件。不過Anne,你還有什麼要補充的嗎?
Anne Whitaker - Company Group Chairman
Anne Whitaker - Company Group Chairman
I just want to reiterate that as well. I feel good about the position that we're in today. We're secure for 2016 and I'm optimistic about expanding access for 2017.
我也想再次強調這一點。我對我們目前所處的位置感到放心。我們在2016年是穩固的,而我也對2017年擴大可近性抱持樂觀。
Specifically on your question around are we bundling versus individual contracts for each of the products. Historically Valeant and the companies it has acquired has really managed individual rebates for each of the products. As we go forward, we'll work with our payer partners and understand that there's value in really leveraging our portfolio.
具體針對你問到的:我們是採打包,還是針對每個產品分別簽訂合約。過去Valeant以及其所收購的公司,確實主要是針對每個產品分別管理個別回扣(rebates)。展望未來,我們會與付款方(payer)夥伴合作,並理解善用我們的產品組合確實具有價值。
You might imagine in areas like ophthalmology, as we prepare to launch new products there, or dermatology, it could be advantageous us to leverage our portfolio. We'll take that on a case-by-case basis and really understand what the payers' needs are as well as our own needs and present a contract offering.
你可以想像,在眼科等領域,當我們準備在那裡推出新產品,或是在皮膚科領域,善用我們的產品組合可能對我們有利。我們會逐案處理,真正了解付款方的需求以及我們自身的需求,並提出合約方案。
Joe Papa - CEO
Joe Papa - CEO
I'm sorry, I know the second part of the question was the negative ASP and Walgreens. Remind me, I'm sorry, I --
抱歉,我知道問題的第二部分是關於負向ASP與Walgreens。提醒我一下,抱歉,我——
Rob Rosiello - CFO
Rob Rosiello - CFO
(multiple speakers) service.
(多位發言者)服務。
Morgan Williams - Analyst
Morgan Williams - Analyst
Does that affect the activity fees?
那會影響活動費嗎?
Joe Papa - CEO
Joe Papa - CEO
No, the simple answer is no. It's a separate negotiated agreement. But I would say certainly as we go and talk to Walgreens about the program, as I said, we think it's a great program. It's a long-term program, it's a 20-year program. But there are going to be these speed bump things that we have to work through. But the negative ASP does not have an impact on the service fees.
不會,簡單的答案是不會。那是一份另外談判的獨立協議。但我會說,當我們去和Walgreens討論這個計畫時,如我所說,我們認為這是一個很棒的計畫。這是一個長期計畫,是一個20年的計畫。但過程中會有一些像減速帶(speed bump)一樣的狀況需要我們去解決。不過,負向ASP不會影響服務費(service fees)。
Morgan Williams - Analyst
Morgan Williams - Analyst
Okay, thank you.
好的,謝謝。
Joe Papa - CEO
Joe Papa - CEO
Operator, next question.
接線員,下一個問題。
Operator
Operator
Doug Miehm, RBC Capital Markets.
Doug Miehm,RBC資本市場。
Doug Miehm - Analyst
Doug Miehm - Analyst
Good morning. I'm sorry to beat this to death, but I just really want to truly understand how we're getting negative ASPs in the Walgreens business on the derm side. You did mention that you got covered lives, you got prior authorization and some cash pay. But could you walk through an analysis of how that actually occurs to get a negative ASP? And then what you can specifically do to address it.
早安。抱歉一直追問,但我真的想徹底理解,在Walgreens業務的皮膚科端,我們是如何出現負向ASP的。你確實提到你們取得了涵蓋人數(covered lives)、取得了事前授權(prior authorization),以及一些自費(cash pay)。但你能否帶我們走一遍分析,說明這究竟是如何發生、以致出現負向ASP?以及你們可以具體做些什麼來解決它。
Joe Papa - CEO
Joe Papa - CEO
Sure. So let me start once again and try to -- I appreciate the question and I need to be more clear on it. Partially reflects my fact that I'm only here 30 days, I think. With the Walgreens program, what happens is that patients come in three different categories.
好的。我再一次從頭說明並嘗試——我很感謝這個問題,我需要把它講得更清楚。部分原因也反映我到任才30天左右,我想。在Walgreens計畫中,病患會以三種不同類別進來。
You're either a cash paying customer, you are a commercial covered customer or you have commercial coverage but there's a prior authorization process. The issue that we come forward with is that in some cases we're actually sending out the product before the prior authorization is being approved.
你要嘛是自費客戶,要嘛是有商業保險給付的客戶,或是你有商業保險但需要經過事前授權流程。我們目前面臨的問題是,在某些情況下,我們其實在事前授權尚未核准前就先把產品寄出了。
And in some cases the prior authorization may be approved, in some cases it may not be approved. As you get to that situation you find yourself in a situation where there is a potential negative ASP when you go across the entire category. That is part of the issue we find ourselves in. There's also within that category we have different co-pays. The different co-pays have an impact on what the actual ASP, or average selling price, is. It is a multitude of factors that come together.
而在某些情況下,事前授權可能會核准,但在另一些情況下可能不會核准。當你落入這種情境時,若把整個類別加總來看,就可能出現負向ASP。這是我們所處困境的一部分原因。此外,在該類別之內我們也有不同的自付額(co-pays)。不同的自付額會影響實際的ASP,也就是平均銷售價格(average selling price)。這是多種因素共同作用的結果。
The reason I believe this can be fixed is that we clearly have the data now. We've got the first quarter behind us. We understand what's happened. We have data. We can look at that data and make decisions about what's the right way to go forward with the program. And that's the reason I have the confidence that it's in Walgreens' interest, it's in Valeant's interest to solve this. And I look forward to trying to solve this with the team at Walgreens.
我之所以相信這可以被修正,是因為我們現在已經清楚掌握數據。第一季已經過去了。我們了解發生了什麼。我們有數據。我們可以檢視這些數據,並就計畫未來應如何推進做出決策。這也是我有信心的原因:解決這件事符合Walgreens的利益,也符合Valeant的利益。我也期待與Walgreens的團隊一起嘗試解決這個問題。
Doug Miehm - Analyst
Doug Miehm - Analyst
Okay, fine.
好的,了解。
Joe Papa - CEO
Joe Papa - CEO
Operator, next question.
接線員,下一個問題。
Doug Miehm - Analyst
Doug Miehm - Analyst
Just a follow-up question with respect to your launches. We'd expect to see latanoprostene and also Relistor Oral. Can you tell us what plans are in place for the launches and when you expect those actual launches to occur? That's it, thanks.
就你們的新產品上市(launches)再追問一題。我們預期會看到latanoprostene以及Relistor口服劑型(Relistor Oral)。你能否告訴我們上市計畫有哪些安排,以及你們預期這些實際上市會在何時發生?就這樣,謝謝。
Joe Papa - CEO
Joe Papa - CEO
Sure. So I think the first thing I'd refer you to is the slide that Tage went through in terms of the timing where we have PDUFA dates for Relistor and latanoprost in July and Broda is in November. Obviously we've got to work through the final stages of getting an FDA approval. I don't want to say exactly when it will happen but we do have PDUFA action dates that we would look forward to interacting with the FDA on those products. So that really is the primary metric in terms of getting the products approved -- or the biggest milestone is getting it through the FDA process.
好的。我想第一點是請你參考Tage講解過的那張投影片,關於時程:Relistor與latanoprost在7月有PDUFA日期,而Broda在11月。顯然我們還必須完成取得FDA核准的最後階段。我不想說得太精確何時會發生,但我們確實有PDUFA的行動日期(action dates),我們也期待就這些產品與FDA互動。因此,就產品核准而言,主要的衡量指標——或最大的里程碑——就是讓它通過FDA流程。
Beyond that, we've got other action steps in place for preparation for it. We had our -- if I talk about latanoprost, for example, we had our entire sales leadership in just, I think it was 10 days ago. They were in to talk about the you launch programs and some of the things we need to accomplish. We've clearly been working on the different prior authorization process and other coverage process that will be required with the product. So we've got a number of series of steps that are built in.
除此之外,我們也已經採取其他行動步驟來為此做準備。例如,如果我以 latanoprost(拉坦前列素)為例,我們在大概 10 天前召集了整個銷售領導團隊。他們來討論上市(launch)方案,以及我們需要完成的一些事項。我們也明確一直在推進產品所需的不同事前授權(prior authorization)流程與其他給付/承保(coverage)流程。因此,我們已經建立了一系列步驟。
We have been somewhat, I would I say, conservative on what we put in for the sales for those for this year until we get more information on exact timing, exact labels, et cetera. But we think that the action steps of getting ready for the launch are under way. It will just be a result of really trying to get to that final labeling, get the product through the final FDA process. I'm going to offer, Tage, do you have any other comments about approval process? I think I've answered that.
在取得更精確的時程、確切標籤(label)等更多資訊之前,我們對今年這些產品的銷售預估可以說相對保守。但我們認為,為上市做準備的各項行動步驟已在進行中。接下來就取決於我們是否能真正完成最終標籤,並讓產品走完 FDA 的最終流程。Tage,我想請你補充一下,你對核准流程還有其他評論嗎?我想我已經回答了。
Tage Ramakrishna - Chief Medical Officer
Tage Ramakrishna - Chief Medical Officer
I think you've covered it.
我想你已經涵蓋了。
Joe Papa - CEO
Joe Papa - CEO
If anyone has any other relative to marketing programs or the access.
如果有人還有其他與行銷方案或市場准入(access)相關的問題。
Anne Whitaker - Company Group Chairman
Anne Whitaker - Company Group Chairman
This is Anne. I would just make one comment with regard to market access timeline. We recognize that in the glaucoma space it's largely a Part B patient population that we'll be going after. So we'll be working through those timelines to hopefully have the product added to formulary next year. We'll be in doubly a solid position for the portfolio and managing that the following year.
我是 Anne。我想就市場准入時程補充一點。我們了解到在青光眼領域,我們主要鎖定的是 Part B 的病患族群。因此,我們會依循這些時程推進,期望能在明年讓產品被納入處方集(formulary)。如此一來,隔年在產品組合(portfolio)與相關管理上,我們會處於更穩固的位置。
For Relistor Oral we'll be working through market access opportunities as well, on the commercial as well as on Part B. I would just caution us a bit that it takes a little longer to get access these days than it used to. We will build that into our planning for each of these launch products.
至於 Relistor 口服劑型(Relistor Oral),我們也會在商業保險以及 Part B 方面推進市場准入機會。不過我想稍微提醒一下,現在取得准入所需的時間比過去更長。我們會把這點納入每一個上市產品的規劃之中。
Joe Papa - CEO
Joe Papa - CEO
That's why we've been conservative on what we put in for sales numbers, what we did put in action steps to get ready for the launch in terms of expenses. Operator, I think we have time for maybe two or three more questions. So next question.
這也是為什麼我們在銷售數字的預估上採取保守態度;但在費用面,我們已投入行動步驟來為上市做準備。接線員,我想我們可能還有時間再回答兩到三個問題。請下一題。
Operator
Operator
Alan Ridgeway, Scotiabank.
Alan Ridgeway,豐業銀行(Scotiabank)。
Alan Ridgeway - Analyst
Alan Ridgeway - Analyst
Good morning, guys. I was hoping we could drill down a little bit more on Xifaxan and what you guys are seeing. If you could potentially provide us with some more color on where the growth is coming from, as far as what you're seeing as far as on the HE side or the IBS side. And if either of those markets is particularly responsible for the under-performance versus your models.
各位早安。我希望我們能更深入談談 Xifaxan,以及你們目前看到的情況。如果可以的話,能否請你們提供更多細節,說明成長主要來自哪裡——例如你們看到的是在 HE 端或 IBS 端的表現。以及這兩個市場中,是否有任何一個特別導致相較你們模型出現未達預期(under-performance)。
And then as a follow-up on that, could you talk to us a little bit about what percentage of the covered lives which you now have really good percentage of covered lives, could you maybe give us some information as to how many of those still require pre-auth or don't require pre-authorization for each of the different labels. So we have a better understanding of how this market might progress. I'll leave it at that, thanks.
接著延伸追問一下,能否談談目前你們已經有很高比例的受保人群(covered lives),其中仍需要事前授權(pre-auth / prior authorization)或不需要事前授權的比例?能否就不同適應症標籤(labels)分別提供一些資訊。這樣我們能更好理解這個市場可能如何發展。我就問到這裡,謝謝。
Joe Papa - CEO
Joe Papa - CEO
Sure, thank you. I want to be clear Salix. It's an interesting comment. We talked about Salix's prescriptions being up 32% year over year. That's in any stretch of any Company, that's a great product performance. So we're very excited about that.
好的,謝謝。我想先釐清一下 Salix。這是一個有意思的評論。我們提到 Salix 的處方量年增 32%。以任何公司的標準來看,這都是非常出色的產品表現。所以我們對此非常振奮。
The issue is, though, that we are seeing some disruption that occurred in our sales force over the 12-month period. That disruption was significant and, therefore, we wanted to make sure that as we thought about the future of this product, that we wanted to be realistic in what it meant for the future. And that's the primary issue.
不過問題在於,我們看到在過去 12 個月期間,我們的銷售團隊出現了一些干擾。那個干擾相當顯著,因此當我們思考這個產品的未來時,我們希望對其未來意涵保持務實。這就是主要問題。
It has less to do with the performance of the product with HE or the performance with IBSD. It had more to do with we saw some disruption in our sales force because of turnover, because of some of the changes. So we felt we needed to be realistic in how we looked at the future performance of the product.
這與產品在 HE 的表現或在 IBSD 的表現關係較小。更多是因為人員流動(turnover)以及一些變動,導致我們的銷售團隊出現干擾。因此我們認為,在評估產品未來表現時,需要更務實。
On the question, though, I think the answer is we find both HE and IBSD as both being very important aspects. The reason HE is really is the best drug for treatment of HE patient in terms of what it means. It's a chronic utilization. So the HE patient is a very important patient for us and one that we think we can make a significant difference in the lives of HE patient and therefore we're going to continue to try to get that message out.
不過就你的問題而言,我想答案是:我們認為 HE 與 IBSD 都是非常重要的面向。之所以 HE 特別重要,是因為就其意義而言,這確實是治療 HE 病患的最佳藥物。它屬於慢性使用。因此 HE 病患對我們非常重要;我們也相信能在 HE 病患的生活上帶來顯著改變,所以我們會持續把這個訊息傳遞出去。
The clear take-away, though, from our slides has to be that if you think about what we're seeing, is that there is not -- there's a large majority of patients that have HE or have the potential to develop HE, are clearly not getting the product yet. And that's something we think that through good programs with physician education, with key opinion leader support and with working with actual patient understanding and sales materials for patients and education materials for patients, we think we can do a better job. And that's really what we're targeted to do.
不過,從我們的投影片可以清楚得到的重點是:如果你看我們目前看到的情況,有很大多數已經有 HE 或有可能發展成 HE 的病患,顯然還沒有使用這個產品。我們認為,透過良好的醫師教育計畫、關鍵意見領袖(KOL)支持,以及與病患溝通理解、提供病患用的銷售資料與教育材料,我們可以做得更好。這正是我們鎖定要做的事情。
But to be clear, it was not performing for the rest of the year at the level that was previously expected and we needed to reduce the number consistent with that. On the second part of the question on the covered lives, Anne, do you want -- we do have a good position with covered lives but maybe comment on the prior authorization.
但要說清楚的是,今年剩餘期間的表現並未達到先前預期的水準,因此我們需要相應地下修數字。至於問題的第二部分、關於受保人群(covered lives),Anne,你要不要——我們在 covered lives 的位置確實不錯,但也許你可以評論一下事前授權(prior authorization)。
Anne Whitaker - Company Group Chairman
Anne Whitaker - Company Group Chairman
Right. So again, we have 98% covered lives. I think with a product like this, to be expected, the payers have utilization management packages in place. So about 40% of the claims that come through for Xifaxan have some sort of utilization management. Most of those are PA, prior authorization, to label. In some cases it might be a quantity limit, given the new IBSD indication. The most common PA that we see is really the PA to the label.
好的。再次說明,我們有 98% 的 covered lives。我想像這樣的產品,保險支付方(payers)會設置使用量管理(utilization management)方案,這是可預期的。因此,大約 40% 送進來的 Xifaxan 理賠申請(claims)會有某種形式的使用量管理。其中多數是 PA(prior authorization,事前授權),也就是依照標籤(label)進行事前授權。在某些情況下,考量到新的 IBSD 適應症,可能會有用量上限(quantity limit)。我們最常見的 PA,確實就是「依標籤」的事前授權。
With regard to your question around IBSD versus HE and the different rates or just different coverage, today we contract Xifaxan as a molecule. We are in conversations with payers about how to differentiate the two indications and provide different access solutions for those different indications. But as of today, we largely contract the molecule.
至於你問到 IBSD 相對於 HE 的差異、或不同費率/不同承保的問題,目前我們是以 Xifaxan 這個分子(molecule)來簽約。我們正在與支付方討論,如何區分這兩個適應症,並針對不同適應症提供不同的准入方案。但截至目前,我們主要仍是以分子層級來簽約。
Joe Papa - CEO
Joe Papa - CEO
Thank you, Anne, for that comment. Operator, we have time for maybe one -- two more questions.
謝謝 Anne 的補充。接線員,我們可能還有時間再回答一題——兩題。
Operator
Operator
David Common, JPMorgan.
David Common,摩根大通(JPMorgan)。
David Common - Analyst
David Common - Analyst
Thanks for squeezing me in. I think it would be a worthwhile confidence-building measure if you would be prepared to share the actual numbers, the numerator and denominator, the figures that go into the ratios for your two debt covenants.
謝謝讓我插進來提問。我認為,如果你們願意分享兩項債務契約(debt covenants)比率中實際使用的數字——分子與分母、也就是構成比率的各項數據——這會是很有助於建立信心的措施。
And my second question which really has nothing to do with my first, if I may, I wonder if I could just characterize your guidance. Would it be the sort of guidance that you're equally likely to exceed and fall short of, a 50/50 case? Or would it be a set of numbers that you're highly confident that you can meet and/or exceed? Thank you.
我的第二個問題,若可以的話,與第一個問題其實無關:我想請問我是否可以這樣描述你們的財測指引(guidance)。它是否屬於你們同樣可能超越或低於的那種指引,也就是 50/50 的情況?或者它是一組你們非常有信心能達成且/或超越的數字?謝謝。
Joe Papa - CEO
Joe Papa - CEO
I'm going to address the second part of your question first and then I'm going to ask Linda if she wants to make any comments on the guidance part. On the second part of the question on guidance, I think I've got to use the word that I used during the commentary, that we try to take a realistic view towards guidance.
我會先回答您問題的第二部分,接著我會請 Linda 看看是否想就指引的部分補充一些意見。關於指引這個問題的第二部分,我想我得用我在評論時用過的那個詞:我們會盡量以務實的角度看待指引。
However, in some areas where there is some uncertainty about exact product launch timing or exact product launch approvals, about things that we don't know exactly when it's going to happen, we try to be somewhat conservative there. Things like the average selling price, we tried to be conservative relative to -- we can get this fixed but we didn't want to build in all that fix because sometimes things like this take some time. So we tried to be conservative as it would relate to areas where we know there's some things that need to be fixed. Because once again, there's a timing question on it.
不過,在某些領域,對於確切的產品上市時點或確切的產品上市核准仍存在一些不確定性,對於一些我們無法精準掌握何時會發生的事情,我們會在那裡採取較為保守的作法。像是平均售價(ASP)這類,我們嘗試相對保守地看待——我們可以把它修正到位,但我們不想把所有修正都納入,因為有時候這類事情需要一些時間。因此,對於我們知道仍有一些需要修正的領域,我們會盡量保守。因為再一次,這裡也牽涉到時點的問題。
But I think in total we've tried to be -- I would phrase the guidance comment as we tried to be realistic with what we know. Where there's some uncertainty on things that need to get done, we tried to be conservative so that there would not be any over-statements in what we're trying to accomplish.
但我認為整體而言,我們已經盡量——我會這樣表述對指引的評論:我們對於已知資訊,力求務實。對於仍有不確定、需要完成的事項,我們會採取保守假設,以避免在我們想達成的目標上出現任何高估。
If we get a quick resolution of ASP, there's clearly some upside. If we get a quick approval and get ready for these launches, get them launched on time, there could be some upside. I think we tried to be conservative in those assumptions where there's some uncertainty in the marketplace. On the question of the -- the first part of the question on the numerator and denominator, Linda, do you want to --
如果 ASP 能快速解決,顯然會有一些上行空間。如果我們能快速取得核准並為這些上市做好準備、按時推出,也可能會有一些上行空間。我想我們在那些市場上仍有不確定性的假設上,已經盡量保守。至於——問題的第一部分,關於分子與分母,Linda,妳要不要——
Linda LaGorga - Treasurer
Linda LaGorga - Treasurer
David, we appreciate your feedback. What we've tried to do this quarter and we said we would do this in a prior call, is we've included adjusted EBITDA which will help people understand that metric. And while I appreciate it's not identical to our credit agreement, I hope it's a helpful piece of additional information.
David,我們感謝你的回饋。我們這一季嘗試做的——而且我們在先前的電話會議中也說過會這麼做——是納入調整後 EBITDA,這將有助於大家理解這個指標。雖然我理解它與我們的信貸協議並非完全一致,但我希望這能提供一項有用的補充資訊。
David Common - Analyst
David Common - Analyst
It is. I appreciate that. Could I also say in the context of this guidance question, since we are about five weeks past your normal release of March quarter figures, I thought it might be worthwhile just to ask how is the June quarter?
確實如此。我很感謝。另外,在這個指引問題的脈絡下,因為現在距離你們通常發布 3 月季度數據已經大約五週了,我想或許值得問一下:6 月季度的情況如何?
Joe Papa - CEO
Joe Papa - CEO
So I think the answer I'm going to say is that we see the June quarter as being favorable to Q1, so clearly that is the first comment I'd offer. I don't think I want to say too much more specifics on it because there's still a lot of moving pieces in the quarter but we do see it is favorable to the first quarter at this time.
所以我想我的回答是:我們認為 6 月季度表現會優於第一季,這顯然是我想先提出的第一點。我不想再講太多更具體的內容,因為這一季仍有很多變動因素,但就目前而言,我們確實看到它優於第一季。
I will point out, though, that Rob did a nice job of showing the bridge of how we're going to build to the guidance for the second half of the year. And the second half of the year has the normal growth that we'll see in the business and the seasonality that we see in the second half of the business. So I don't want people to get too far ahead of us relative to the second quarter. Rob, anything you want to add?
不過我要指出的是,Rob 很好地展示了我們如何搭建到下半年指引的橋接。而下半年包含我們在業務中通常會看到的成長,以及我們在下半年業務中看到的季節性。所以我不希望大家相對於第二季把預期拉得太前面。Rob,你有什麼想補充的嗎?
David Common - Analyst
David Common - Analyst
Thank you.
謝謝。
Operator
Operator
Operator, I think we have time for one last question. Gregg Gilbert, Deutsche Bank.
接線員,我想我們還有時間再回答最後一個問題。Deutsche Bank 的 Gregg Gilbert。
Gregg Gilbert - Analyst
Gregg Gilbert - Analyst
Yes. Can you comment on your cash tax rate in the mid single-digits, Rob, and how sustainable you think that is? Is there a rule of thumb to think about where that can go over time and based on different variables? Thanks.
是的。Rob,你能否評論一下你們現金稅率在中個位數(mid single-digits)的情況,以及你認為這有多可持續?是否有一個經驗法則可以用來思考它隨時間可能如何變化,以及取決於哪些不同變數?謝謝。
Joe Papa - CEO
Joe Papa - CEO
Gregg, I think we're very fortunate that we have Rob here to answer this question. We have some other additional tax expertise. So Rob, I'll turn it to you first.
Gregg,我想我們很幸運有 Rob 在這裡回答這個問題。我們也有其他額外的稅務專業資源。所以 Rob,我先把問題交給你。
Rob Rosiello - CFO
Rob Rosiello - CFO
Cash taxes made up the two factors which we're not breaking out the -- we're only breaking out the effective tax rate of the non-GAAP measures. Our cash tax rate includes the effect of the NOLs that will last roughly -- and I'll let Jeremy comment on the timing of those.
現金稅主要由兩個因素構成;我們不會拆分——我們只會拆分非 GAAP 指標的有效稅率。我們的現金稅率包含 NOL(淨營業虧損結轉)影響,這些大約會持續——我會讓 Jeremy 補充其時點。
Jeremy Lipshy - Director of Tax Planning
Jeremy Lipshy - Director of Tax Planning
So our cash tax will be reflective of the use of tax attributes such as NOLs and credit as well as other timing items. Our NOLs are projected to last for the next three years or so within the US and about 10 years in Canada. So we think that will be from a cash tax perspective, an effective tax rate in the single-digits for the next five years.
因此,我們的現金稅將反映稅務屬性(例如 NOL 與稅額抵減)以及其他時點性項目的使用。我們預計在美國的 NOL 大約還能使用未來三年左右,在加拿大約 10 年。所以從現金稅的角度來看,我們認為未來五年有效稅率會維持在個位數。
Joe Papa - CEO
Joe Papa - CEO
Thank you, Jeremy. If we're going to bring this call to a close, I first of all wanted to thank everyone for joining us today. I understand there's a lot more information I need to provide and we tried to make today a little bit more than just an average quarter because I really wanted to talk about some of the things we are looking at strategically in terms of the stabilizing of the Company and what we're trying to do.
謝謝你,Jeremy。在我們準備結束本次電話會議之際,我首先要感謝各位今天加入我們。我知道我還需要提供更多資訊,而我們也嘗試讓今天的內容不只是一般季度的例行說明,因為我真的想談談一些我們在策略上所關注的事項,包括公司穩定化以及我們想要做的事情。
Having said that, we know there's a lot more we need to answer at a future call. I look forward to talking more about the turnaround program and the transformation program of the Company.
話雖如此,我們也知道在未來的電話會議上,還有很多問題需要回答。我期待能更深入談談公司的扭轉計畫與轉型計畫。
But I wanted to keep my comments today mostly to what I would refer to as a stabilization program and how we're going to fix the derm business, how we're going to accelerate the Xifaxan growth, how we look at the business on the Bausch & Lomb assets and what we think is a very durable nature of those assets. To me that's what was one of the important things.
但我希望今天的評論主要聚焦在我所稱的「穩定化計畫」:我們將如何修復皮膚科(derm)業務、如何加速 Xifaxan 的成長、我們如何看待 Bausch & Lomb 資產的業務,以及我們認為這些資產具備非常持久的特性。對我而言,那是其中一個重要重點。
I also wanted to make sure we had a chance to make people comfortable, that they understand the liquidity and that we have a strong liquidity position. We are comfortable with our debt covenants relative to how we find ourselves.
我也想確保我們有機會讓大家安心,讓大家理解流動性狀況,並且我們擁有強勁的流動性部位。就我們目前的處境而言,我們對於債務契約條款(covenants)感到放心。
And there was an interesting question that I probably want to spend a second on. The question is our GAAP projections for earnings. We clearly have those but I think what we've tried to do is give people an understanding of our adjusted earnings because that really is what we think is really important for people to understand going into the future.
另外有一個有趣的問題,我可能想花一點時間談一下。問題是我們依 GAAP 的盈餘預測。我們當然有那些預測,但我認為我們嘗試做的是讓大家理解我們的調整後盈餘,因為那才是我們認為對大家理解未來最重要的部分。
So I think I tried to cover all the items but I, once again, would say thank you very much. I look forward to getting out there and telling you more about what we see as some of the excitement in the future, especially with some of the things that Tage talked about, which I think is the real exciting, is how we're going to improve people's lives by launching new innovative products that make a difference in people's lives.
所以我想我已經涵蓋了所有項目,但我再次要說:非常感謝。我期待能走出去,向各位分享更多我們對未來一些令人振奮之處的看法,特別是 Tage 談到的一些事情;我認為真正令人興奮的是,我們將如何透過推出能改變人們生活的新型創新產品,來改善人們的生活。
To me, that's the excitement. I look forward to having more conversations with all of our shareholders and debt holders in the future. Thank you for joining us today. Have a great day.
對我而言,那就是令人振奮之處。我期待未來能與我們所有股東與債權人有更多交流。感謝各位今天加入我們。祝各位有美好的一天。
Operator
Operator
Ladies and gentlemen, this concludes today's conference call. You may now disconnect.
各位女士、先生,本日電話會議到此結束。您現在可以掛線。